

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 785 212 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
23.07.1997 Bulletin 1997/30

(51) Int. Cl.⁶: **C07J 7/00**, A61K 31/57,
C07J 53/00, C07J 41/00
// C07J71/00, C07J21/00

(21) Application number: 96400146.5

(22) Date of filing: 22.01.1996

(84) Designated Contracting States:
FR

(71) Applicant: **LABORATOIRE THERAMEX**
98000 Monaco (MC)


(72) Inventors:
• **Piasco, Alain**
F-06100 Nice (FR)
• **Lafay, Jean**
F-06100 Nice (FR)

• **Delansorne, Rémi**
F-06000 Nice (FR)
• **Paris, Jacques**
F-06100 Nice (FR)
• **Pascal, Jean-Claude**
F-6200 Villefranche sur Mer (FR)

(74) Representative: **Gillard, Marie-Louise**
Cabinet Beau de Loménie
158, rue de l'Université
75340 Paris Cédex 07 (FR)

(54) **New 19-nor-pregnene derivatives**

(57) The invention relates to compounds of the formula :



wherein :

R_1 , R_2 , R_3 , R_4 and R_6 each independently represent hydrogen or a (C₁-C₆)alkyl,
 R_5 is hydrogen, a (C₁-C₆)alkyl or a group -COR₇ where R_7 is a (C₁-C₆)alkyl,
 n is zero or one, and
 X is oxygen or an hydroxyimino group,
provided that when $n = 0$, at least two of R_1 , R_2 , R_3 and R_4 are different from hydrogen and that when $n = 1$, R_3 and R_4 are not simultaneously hydrogen,
and to pharmaceutical compositions containing them.

These compounds are excellent progestogens and are devoid of residual androgenic activity.


EP 0 785 212 A1

Description

The invention relates to substituted 19-nor-pregnene derivatives, methods of making these compounds and pharmaceutical compositions containing them.

The compounds according to this invention have specific and powerful progestative properties, and are devoid of residual androgenic activity.


19-nor-pregnene derivatives substituted in position 1,2 - have been described in the literature. For example, FR-A-1 525 916 relates to a method of preparing compounds of the formula :



in which R is hydrogen or an acyl residue such as acetyl or hexanoyl.


In addition, 19-nor-pregnene derivatives substituted in position 6- are described in the following documents :

- * FR-A-1 524 013 which relates to 3-enol ether pregnane derivatives obtained from the 4-pregnene-3,20-diones of the formula :



among which 6 α -methyl-17 α -hydroxy-4-pregnene-3,20-dione may be cited ;

- * DE-A-2 148 261 which describes a method of preparing 6 α -methyl-19-nor-pregnenes of the formula :



in which R_1 is hydrogen or methyl and R_2 is (C_1-C_9) alkyl ; or


BE 757 285 which relates to pharmaceuticals containing 3,20-dioxo-6 α -methyl-17 α -acetoxy-19-nor- Δ^4 -pregnene.

19-nor-pregnene derivatives such as those described above usually exhibit however androgenic side effects.

On the other hand, the conversion of 17 α , 20-isopropylidenedioxy-4,5-seco-3-pregnyn-5-one to 6,6-dimethyl-17 α -hydroxyprogesterone is disclosed in US 3,891,677.

The Applicant has now found that 19-nor-pregnene derivatives which possess at least two substituents in position 1-, 2-, 1,2- and/or 6-, display a potent progestative activity while being devoid of residual androgenic activity.

A first aspect of this invention thus encompasses compounds having the structure represented by the following general formula (I) :



wherein :

R_1 , R_2 , R_3 , R_4 and R_6 each independently represent hydrogen or a (C_1-C_6) alkyl,

R_5 is hydrogen, a (C_1-C_6) alkyl or a group $-COR_7$ where R_7 is a (C_1-C_6) alkyl,

n is zero or one, and

X is oxygen or an hydroxyimino group,

provided that when $n = 0$, at least two of R_1 , R_2 , R_3 and R_4 are different from hydrogen and that when $n = 1$, R_3 and R_4 are not simultaneously hydrogen.

As used herein, the term "alkyl" means a branched or unbranched saturated hydrocarbon radical, such as for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.

As used herein the group $-COR_7$ wherein R_7 is a (C_1-C_6) alkyl includes, for example, acetyl, propionyl, butyryl, isobutyryl, t-butyryl, valeryl and hexanoyl, acetyl being preferred.

Preferred compounds of formula (I) are those wherein R_1 , R_2 and R_6 are hydrogen, R_3 and R_4 are a (C_1-C_6) alkyl, R_5 is a group $-COR_7$ and n is zero, those where X is oxygen being especially preferred. Also preferred are the compounds of formula (I) wherein R_1 , R_2 , R_4 and R_6 are hydrogen, R_3 is a (C_1-C_6) alkyl, R_5 is a group $-COR_7$ and n is one. Further preferred are the compounds of formula (I) wherein R_4 and R_6 are hydrogen, R_3 is a (C_1-C_6) alkyl, R_5 is a group $-COR_7$ and n is zero. Among the latter, those where R_1 is hydrogen and R_2 is a (C_1-C_6) alkyl and those where R_1 is a (C_1-C_6) alkyl and R_2 is hydrogen are also preferred, those where X is oxygen being especially preferred.

The diagram illustrates a complex biosynthetic pathway for a steroid molecule, starting from precursor 2 and leading to product 12. The intermediates and their transformations are as follows:

- 2** (top right) is a steroid with a Δ^5 double bond, a Δ^6 double bond, and a Δ^7 double bond. It has a $\text{CH}_2\text{-R}_6$ group at C-13 and an OR_5 group at C-14. It is converted to **3** (top left) and **1** (middle right).
- 3** is a steroid with a Δ^5 double bond, a Δ^6 double bond, and a Δ^7 double bond. It has a $\text{CH}_2\text{-R}_6$ group at C-13 and an OR_5 group at C-14. It is converted to **4** (middle left).
- 4** is a steroid with a Δ^5 double bond, a Δ^6 double bond, and a Δ^7 double bond. It has a $\text{CH}_2\text{-R}_6$ group at C-13 and an OR_5 group at C-14. It is converted to **5** (bottom left).
- 5** is a steroid with a Δ^5 double bond, a Δ^6 double bond, and a Δ^7 double bond. It has a $\text{CH}_2\text{-R}_6$ group at C-13 and an OR_5 group at C-14. It is converted to **6** (bottom middle right).
- 6** is a steroid with a Δ^5 double bond, a Δ^6 double bond, and a Δ^7 double bond. It has a $\text{CH}_2\text{-R}_6$ group at C-13 and an OR_5 group at C-14. It is converted to **7** (bottom middle left).
- 7** is a steroid with a Δ^5 double bond, a Δ^6 double bond, and a Δ^7 double bond. It has a $\text{CH}_2\text{-R}_6$ group at C-13 and an OR_5 group at C-14. It is converted to **8** (bottom left), **9** (bottom middle left), and **10** (bottom left).
- 8** is a steroid with a Δ^5 double bond, a Δ^6 double bond, and a Δ^7 double bond. It has a $\text{CH}_2\text{-R}_6$ group at C-13 and an OR_5 group at C-14. It is converted to **9** (bottom middle left).
- 9** is a steroid with a Δ^5 double bond, a Δ^6 double bond, and a Δ^7 double bond. It has a $\text{CH}_2\text{-R}_6$ group at C-13 and an OR_5 group at C-14. It is converted to **10** (bottom left).
- 10** is a steroid with a Δ^5 double bond, a Δ^6 double bond, and a Δ^7 double bond. It has a $\text{CH}_2\text{-R}_6$ group at C-13 and an OR_5 group at C-14. It is converted to **11** (bottom right).
- 11** is a steroid with a Δ^5 double bond, a Δ^6 double bond, and a Δ^7 double bond. It has a $\text{CH}_2\text{-R}_6$ group at C-13 and an OR_5 group at C-14. It is converted to **12** (bottom right).
- 12** is a steroid with a Δ^5 double bond, a Δ^6 double bond, and a Δ^7 double bond. It has a $\text{CH}_2\text{-R}_6$ group at C-13 and an OR_5 group at C-14. It is converted to **11** (bottom right).

The structures are labeled with R_1 , R_2 , R_3 , R_4 , R_5 , and R_6 substituents. The $\text{CH}_2\text{-R}_6$ group is attached to C-13, and the OR_5 group is attached to C-14. The R_1 and R_2 groups are attached to C-10 and C-13, respectively. The R_3 and R_4 groups are attached to C-14 and C-15, respectively. The R_5 group is attached to C-16. The R_6 group is attached to C-17. The X group is attached to C-18.

4

Compounds **1** are prepared using a process similar to that described in DE-A-2 148 261. In the case where $R_5 = -COR_7$, they are saponified by sodium hydroxide in a mixture of ethanol and tetrahydrofuran. Products **1** ($R_5 = H$) are separated by precipitation on water followed by crystallization in an alcohol, preferably methanol or ethanol. Then, they are dissolved in toluene to which is added 1 to 10 molar equivalents of ethylene glycol, preferably 5 molar equivalents, triethylorthoformate and a catalytic amount of *p*-toluenesulfonic acid. The reaction mixture is stirred at a temperature of about 20°C to 80°C, preferably 40°C for about 2 to 8 hours. The reaction mixture is cooled and poured into iced water and extracted with a suitable organic solvent. The residue obtained after evaporation of the solvent can be purified by crystallization or by flash-chromatography to yield the compounds **2**.

Treatment of compounds **2** with 3-chloroperoxybenzoic acid (MCPBA) in methylene chloride gives a mixture of 5,6-oxiranes **3** which are separated by crystallization or by flash-chromatography. Addition of an excess of R_4 -magnesium-halide to the compounds **3** in tetrahydrofuran at a temperature of about 20°C to 60°C for about 8 hours, and treatment of the reaction mixture with a solution of ammonium chloride and extraction with toluene and evaporation of the solvent gives the compounds **4**.

Deprotection followed by deshydration of the tertiary hydroxy group gives the compounds **5** which can be optionally esterified by known processes used for esterification in steroid chemistry or etherified by an alkyl halide according to conventional methods of Williamson ether synthesis such as that described by B.G. Zupancic and M. Sopic, *Synthesis*, 1979, 123 or by D.R. Benedict et al., *Synthesis*, 1979, 428-9.

Compounds **6** where R_3 is (C_1 - C_6)alkyl and R_4 is hydrogen can be prepared as follows :

Compounds **6** with the 5 β -H configuration are obtained by hydrogenation of compounds **1** or **5** in tetrahydrofuran, acetic acid or an alcohol such as methanol, ethanol or propanol, with palladium or a palladium or platinum derivative.

Compounds **6** with the 5 α -H configuration can be obtained by chemical reduction of compounds **1** or **5** with sodium dithionite using a procedure described by F. Camps et al., *Tetrahedron Lett.*, 1986, 42, n°16, 4603-4609 or R.S. Dhillon et al., *Tetrahedron Lett.*, 1995, 36, n°7, 1107-8.

The compounds of formula (I) can be obtained as follows :

Bromination followed by dehydrobromination of the compounds **6** according to wellknown techniques (Y.J. Abul-Hajj, *J. Org. Chem.*, 1986, 51, 3059-61; C. Djerassi and C.R. Scholz, *J. Am. Chem. Soc.*, 1948, 417; R. Joly et al., *Bull. Soc. Chim. Fr.*, 1957, 366) gives the compounds **7** ($R_1 = R_2 = H$).

Compounds **5** ($R_5 = H$) can be transformed to their 20,20-ethanedioxy derivatives then converted to their 2-hydroxymethylene sodium salt and alkylated using an alkyl iodide such as methyl iodide, ethyl iodide or propyl iodide following the method described by N.W. Atwater et al. in *J. Org. Chem.*, 1961, 23, 3077-83 to obtain compounds **10** ($R_1 = H$, $R_2 = \text{alkyl}$, $n=0$).

Optionally, chemical reduction by hydrogenation of the 4,5-double bond of compounds **10** ($R_1 = H$, $R_2 = \text{alkyl}$, $n = 0$), followed by bromination/dehydrobromination gives compounds **7** ($R_1 = H$, $R_2 = \text{alkyl}$).

Addition of a lithium dialkylcuprate $LiCu(R_1)_2$ or of the corresponding alkylmagnesium halide under copper catalysis (for example CuI, CuCl or CuCN) to compounds **7** ($R_1 = R_2 = H$) gives compounds **12** ($R_1 = \text{alkyl}$) which can be converted to compounds **10** ($R_1 = \text{alkyl}$, $R_2 = H$, $n = 0$) using well-known techniques for the introduction of 4,5-double bond in steroid chemistry, or transformed to compounds **7** ($R_1 = \text{alkyl}$, $R_2 = H$) by dehydrogenation or by bromination/dehydrobromination. Compounds **12** can also be alkylated in position 2- by a similar process to obtain compounds **10** ($R_2 = \text{alkyl}$, $n = 0$) which are then converted to compounds **7** ($R_1 = R_2 = \text{alkyl}$) as described above.

Compounds **9** ($R_1 = H$ or alkyl, $R_2 = H$ or alkyl, $n = 1$) are prepared by reaction of compounds **7** ($R_1 = H$ or alkyl, $R_2 = H$ or alkyl) with a dimethylsulfoxonium methylide produced by the reaction of trimethylsulfoxonium iodide (with a base preferably) with sodium hydride in tetrahydrofuran, dimethylformamide or dimethylsulfoxide. They can also be prepared by reaction of compounds **7** with diazomethane catalyzed by palladium or copper derivatives. Alternatively, compounds **7** ($R_1 = H$ or alkyl, $R_2 = H$ or alkyl) can be reduced with sodium borohydride in the presence of cerium chloride into compounds **8** ($R_1 = H$ or alkyl, $R_2 = H$ or alkyl) which are submitted to a Simmons-Smith reaction according to various known described procedures (H.E. Simmons and R.D. Smith, *J. Am. Chem. Soc.*, 1958, 80, 5323; H.E. Simmons and R.D. Smith, *J. Am. Chem. Soc.*, 1959, 81, 4256; *Org. Synthesis*, 1961, 41, 72; J. Furukawa et al., *Tetrahedron Lett.*, 1966, 3353; J. Furukawa et al., *Tetrahedron* 1968, 24, 53; S.E. Denmark and Edwards, *J. Org. Chem.*, 1991, 56, 6974-81).

Oxidation of the 3-hydroxy group of compounds **8** with various oxidizing agents such as CrO_3 /pyridine gives compounds **9**.

Compounds **9** ($R_1 = H$ or alkyl, $R_2 = H$ or alkyl, $n = 0$ or 1) are converted to their silyl enol ether and dehydrogenated with palladium acetate in refluxing acetonitrile to give compounds **10**. Alternatively, the 4,5-double bond can be introduced by bromination followed by dehydrobromination using a process similar to that described above for compounds **7**. Condensation of compounds **10** with hydroxylamine hydrochloride in a mixture of dioxane and pyridine gives compounds **11**.

The compounds according to this invention have specific and powerful progestative properties. Therefore they are useful for the treatment of a variety of endocrine-gynaecological disorders, either related to an oestrogen/progesterone imbalance, including menstrual disorders (spaniomenorrhea, oligomenorrhea, secondary amenorrhea, premenstrual

tension, headache, water retention, mood alteration), breast disorders (cyclical mastalgia, benign breast disease, breast tumors), endometrial diseases (hyperplasia, pre-malignant alteration tumors) ; or conditions requiring inhibition of gonadotropic/gonadal secretions: endometriosis, polycystic ovary syndrome in women, prostate diseases in men.

On the other hand, the compounds according to the invention can be used as contraceptive agents, either alone or in combination with an affective amount of sex steroid such as oestradiol, ethinyl oestradiol or testosterone, and again alone or in combination with an oestrogen for hormonal replacement therapy in postmenopausal women.

The progestative activity of the compounds according to the present invention can be assessed mainly in two specific experimental models the affinity for the progesterone receptor (PR) *in vitro*, and the endometrial transformation of the rabbit uterus *in vivo*.

Human PR are readily available in high amounts from the T47-D cell line in culture (M.B. Mockus et al., *Endocrinology*, 1982, 110, 1564-1571). Relative binding affinities (RBA) for the human T47-D cell PR are determined as previously described (J. Botella, et al., *J. Steroid Biochem. Molec. Biol.*, 1994, 50, 41-47) using [³H]-ORG 2058 as a labelled specific ligand (G. Fleischmann and M. Beato, *Biochim. Biophys. Acta*, 1978, 540, 500-517) and norgestrol acetate as a non-radioactive reference progestin.

Competitive incubations were performed against 2 nM of [³H]-ORG 2058 for 3 hours at 4°C with six different concentrations of non-labelled steroid, chosen between 4 and 256 nM following a 1/2ⁿ dilution scheme. Displacement curves were fitted for each experiment, and the concentration inhibiting 50% of the specific binding of [³H]-ORG 2058 was calculated for each curve (IC₅₀).

Table 1

Relative binding affinity to human T47-D cell progesterone receptor			
Progestin	IC ₅₀ ^(a) in nM	(n)	RBA
Norgestrol acetate	8.9 ± 2.0	(8)	100 %
Compound of example 1	27.8 ± 2.0	(4)	32 %
Compound of example 4	22.8 ± 1.7	(4)	39 %
Compound of example 5	17.7 ± 2.4	(4)	50 %

(a) mean ± s.e.m. ;

(n) number of experiments

One specific pharmacological test has been standardized *in vivo* for the detection and quantitation of pseudogestagenic activity since the mid-30's : it is based on the property of the uterus of estrogen-primed immature female rabbits to respond to very slight amounts of progestin by a typical endometrial transformation into a densely packed and interlaced epithelial network called "dentelle". The original test schedule, which includes 6 days of estrogen priming (total subcutaneous dose of 30 µg/rabbit of oestradiol benzoate) followed by 5 days of progestative treatment, was designed as early as 1930 by C. Clauberg, *Zentr. Gynäkol.* 1930, 54, 2757-2770. The semi-quantitative scale used to grade the intensity of the microscopical appearance of the dentelle was set up by M.K. McPhail, *J. Physiol* (London), 1934, 83, 145-156. This overall Clauberg-McPhail procedure has been extensively used to screen steroids for putative progestative activity *in vivo* and is still part of the basic hormonal profile of any new progestin such as norgestimate (A Phillips et al., *Contraception*, 1987, 36, 181-192), or desogestrel (J. Van der Vies and J. De Visser, *Arzneim. Forsch./Drug Res.*, 1983, 33, 231-236).

The progestative potency is inversely related to the dose needed to induce a half-maximal stimulation of the dentelle, i.e. to record a mean McPhail grade equal to 2. This ED₅₀ is deduced from the dose-response curve and expressed in total dose/rabbit/5 days. All compounds were tested only following oral administration by gavage, in suspension in a carboxy-methylcellulose solution. The maximal dose administered was 1 mg, roughly corresponding to 5 times the ED₅₀ of norgestrol acetate, a potent orally active 19-norprogesterone-derived progestin (J. Paris et al., *Arzneim. Forsch./Drug Res.*, 1983, 33, 710-715).

Table 2

Clauberg-McPhail test by oral administration (gavage)			
Progestin	ED ₅₀ ^(a) (mg/rabbit/5 days)	(n)	Relative activity
Nomegestrol acetate	170 ± 41	(5)	100 %
Example 1	152 ± 28	(3)	112 %
Example 4	66 ± 11	(2)	258 %
Example 5	> 750 ± 6.0	(1)	< 17 %

(a) mean ± s.e.m. ;

(n) number of experiments

The residual androgenic potential is an important feature to be evaluated for any new progestin, because it is highly predictive of androgenic side-effects in women. One pharmacological model of androgenic activity has been standardized to screen steroids or related compounds in immature castrated male rats, using the hypertrophy of the ventral prostate and of the seminal vesicle as the endpoint, following 10 daily administrations (R.I. Dorfman, in *Methods in Hormone Research*, volume 2, London, Academic Press, 1962 : 275-313 ; A.G. Hilgar and D.J. Hummel, *Androgenic and Myogenic Endocrine Bioassay Data*, U.S. Department of Health, Education and Welfare, Washington D.C., 1964). Medroxyprogesterone acetate is a 6 α -methylpregnene derivative which, besides its main progestative activity, is well-known for its weak androgenic properties (M. Tausk and J. de Visser, In *International Encyclopedia of Pharmacology and Therapeutics*; Section 48 : Progesterone, Progestational Drugs and Antifertility Agents, volume II, OXFORD, Pergamon Press, 1972 : 35-216); it was therefore chosen as a reference compound in the testing for residual androgenic activity of some compounds according to the invention .

Compounds of examples 1 and 4 were tested for residual androgenic activity in the immature castrated male rat model by gavage (PO), in comparison, respectively, with medroxyprogesterone acetate and cyproterone acetate (a 1,2 α -cyclomethylene pregnene derivative with potent progestative activity) ; testosterone was used as a standard androgenic agent by subcutaneous injection (SC).

Table 3

Residual androgenic activity of the compound of example 1			
Steroid	Dose (mg/animal/day)	Ventral Prostate (mg)	Seminal Vesicle (mg)
Castrated controls	-	12.0 ± 0.9	12.3 ± 0.7
Testosterone, SC	0.05	90.4 ± 4.4***	90.3 ± 6.7***
Medroxyprogesterone acetate, PO	20	29.1 ± 1.4***	19.9 ± 1.8**
Example 1, PO	20	13.0 ± 0.3 ns	10.4 ± 0.5 ns
mean ± s.e.m. of 8 animals per group ;			

** p < 0.001 and

*** p < 0.001

ns : not statistically different from controls.

Table 4

Residual androgenic activity of the compound of example 4			
Steroid	Dose (mg/animal/day)	Ventral Prostate (mg)	Seminal Vesicle (mg)
Castrated controls	-	11.8 ± 0.6	10.4 ± 0.6
Testosterone, SC	0.05	80.9 ± 3.4***	79.0 ± 5.3***
Cyprotérone acetate, PO	20	15.3 ± 1.3*	11.3 ± 0.6 ns
Example 4, PO	20	12.1 ± 0.4 ns	11.2 ± 0.5 ns
mean ± s.e.m. of 7 or 8 animals per group ;			

* p < 0.05 and

*** p < 0.001

ns : not statistically different from controls.

The compounds of examples 1 and 4 were totally inactive on the growth of male accessory sex organs (Tables 3 and 4). The stimulatory effect of cyproterone acetate was very weak and limited to the ventral prostate, at the border of statistical significance (Table 4), while medroxyprogesterone acetate caused both organs to more or less double in weight (Table 3).

Thus, the compounds according to the present invention are potent progestogens devoid of any residual androgenic activity.

Thus according to another aspect, the invention relates to pharmaceutical compositions containing an effective amount of a compound of formula (I), mixed with suitable pharmaceutically acceptable excipients. Said compositions may further comprise an effective amount of an oestrogen.

Another aspect of the invention comprises a method of treating or preventing endocrine - gynaecological disorders, and a method of inhibiting gonadotropic/gonadal secretions.

The compounds according to the present invention can be administered at therapeutically effective dosage for each condition mentioned above. Administration of the active compounds described herein can be via any of the accepted modes of administration for agents that serve similar utilities.

The usual, necessary daily dose of the compound according to the invention will be in the range of 0.001 to 1 mg/kg of body weight per day of the active compound of formula (I). Most conditions respond to a treatment comprising a dosage level on the order of 0.002 to 0.2 mg/kg of body weight per day. Thus, for administration to a 50 kg person, the dosage range would be about 1 mg per day, preferably between about 0.1 to 10 mg per day.

Depending on the specific clinical status of the disease, administration can be given via any accepted systemic delivery system, for example, via oral route or parenteral route such as intravenous, intramuscular, subcutaneous or percutaneous route, or vaginal, ocular or nasal route, in the form of solid, semi-solid or liquid dosage forms, such as for example, tablets, suppositories, pills, capsules, powders, solutions, suspensions, cream, gel, implant, patch, pessary, aerosols, collyrium, emulsions or the like, preferably in unit dosage forms suitable for easy administration of fixed dosages. The pharmaceutical compositions will include a conventional carrier or vehicle and a compound of formula (I) and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.

If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.

The compounds of this invention are generally administered as a pharmaceutical composition which comprises a pharmaceutical vehicle in combination with a compound of Formula (I). The level of the drug in a formulation can vary within the full range employed by those skilled in the art, e.g., from about 0.01 weight percent (wt%) to about 99.99 wt% of the drug based on the total formulation and about 0.01 wt% to 99.99 wt% excipient.

The preferred mode of administration, for the conditions mentioned above, is oral administration using a convenient daily dosage regimen which can be adjusted according to the degree of the complaint. For said oral administration, a pharmaceutically acceptable, non-toxic composition is formed by the incorporation of the selected compound of formula (I) in any of the currently used excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, gelatin, sucrose, magnesium carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain between 0.01 wt% and 99.99 wt% of the active compound

according to this invention.

Preferably the compositions will have the form of a sugar coated pill or tablet and thus they will contain, along with the active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, and the like ; a disintegrant such as starch or derivatives thereof ; a lubricant such as a magnesium stearate and the like ; and a binder such as a starch, polyvinylpyrrolidone, acacia gum, gelatin, cellulose and derivatives thereof, and the like.

The invention is now illustrated by the examples below. In these examples, the following abbreviations are used :

s : singlet
d : doublet
t : triplet
q : quadruplet
m : multiplet
dd : doubled doublet
bs : broad singlet

EXAMPLE 1 : 17 α -acetoxy-6,6-dimethyl-3,20-dioxo-19-nor-pregna-4-ene (5)

A/ 17 α -hydroxy-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene (1)

To a solution of 17 α -acetoxy-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene (100 g, 268 mmol.) in absolute ethanol and tetrahydrofuran (200 mL) was added, in 45 min. at room temperature, 1N sodium hydroxyde (300 mL, 300 mmol.). The solution was stirred (8 hours) and poured into iced water (4000 mL). The precipitate was filtered and dried at 50°C over vacuum (yield: 70 g, 78.9 %), mp : 172°C.

¹H-NMR (CDCl₃, δ) : 0.79 (s, 3H) ; 1.25 (d, 3H) ; 2.29 (s, 3H) ; 2.68 (m, 1H) ; 5.87 (s, 1H).

B/ Bis-[3,3-20,20-ethanedioxy]-17 α -hydroxy-6-methyl-19-nor-pregna-5-ene (2)

To a suspension of compound 1 (70 g, 211 mmol.) in anhydrous ethylene glycol (1000 mL), acetonitrile (700 mL) and triethylorthoformate (105 mL, 633 mmol.) was added para-toluenesulfonic acid monohydrate (5.25 g, 27.6 mmol.). The mixture was stirred (2 hours) and neutralized by triethylamine (8 mL, 57.4 mmol.). After concentration to 1000 mL, the suspension was poured into water (4000 mL). The precipitate was filtered and dried at 60°C over vacuum (yield : 81 g, 92.1%), mp : 214°C.

¹H-NMR (CDCl₃, δ) : 0.85 (s, 3H) ; 1.40 (s, 3H) ; 1.65 (s, 3H) ; 2.80 (m, 1H) ; 4.00 (m, 8H).

C/ 5 α ,6 α -epoxy-bis[3,3-20,20-ethanedioxy]-17 α -hydroxy-6 β -methyl-19-nor-pregnane (3)

To a solution of compound 2 (70 g, 167 mmol.) in methylene chloride (800 mL) was added a 80 % solution of 3-chloroperoxybenzoic acid (43.29 g, 200.17 mmol.) in methylene chloride (250 mL). The reaction mixture was stirred for 1 hour. The precipitate was filtered and the organic phase was washed with NaHSO₃ and with a solution of hydrogen sodium carbonate. The organic phase was dried (Na₂SO₄), concentrated and the residue was flash-chromatographed on silica gel using toluene/ethyl acetate as eluting solvent to give 20.3 g of the title compound (yield : 27.63 %), mp : 220°C.

¹H-NMR (CDCl₃, δ) : 0.80 (s, 3H) ; 1.25 (s, 3H) ; 1.35 (s, 3H) ; 4.00 (m, 8H).

D/ Bis[3,3-20,20-ethanedioxy]-5 α ,17 α -dihydroxy-6,6-dimethyl-19-nor-pregnane (4)

To a solution of compound 3 (30 g, 69 mmol.) in tetrahydrofuran (1200 mL) was added 1.4 M methyl magnesium bromide in a tetrahydrofuran/toluene mixture (250 mL, 345 mmol.). The solution was stirred at reflux overnight. The mixture was poured into a solution of ice and saturated ammonium chloride (1000 mL). The reaction mixture was extracted with toluene, washed by water and dried (Na₂SO₄). Evaporation of the solvent gave a residue which was chromatographed using toluene/ethyl acetate as eluting solvent (yield: 15.4 g, 49.55 %), mp : 212°C.

¹H-NMR (CDCl₃, δ) : 0.85 (s, 3H) ; 0.95 (s, 6H) ; 1.35 (s, 3H) ; 4.00 (m, 8H).

E/ 17 α -acetoxy-6,6-dimethyl-3,20-dioxo-19-nor-pregna-4-ene

To the above compound (30.8 g, 68.33 mmol.) in acetone (300 mL) and water (30 mL) was added para-toluenesulfonic acid monohydrate (1.33 g, 7 mmol.). The reaction mixture was stirred at room temperature for 5 hours. After neutralisation with NaHCO₃, the mixture was poured into iced water (100 mL) and extracted twice with methylene chloride. The organic layer was washed with water, dried (Na₂SO₄) and concentrated to give 24.3 g of 5 α ,17 α -dihydroxy-6,6-dimethyl-3,20-dioxo-19-nor-pregnane (yield : 98.2 %), mp : 224°C.

¹H-NMR (CDCl₃, δ) : 0.75 (s, 3H) ; 0.91 (s, 3H) ; 1.08 (s, 3H) ; 2.29 (s, 3H).

To a solution of this compound (15 g, 41.20 mmol.) in acetic acid (120 mL) was added a few drops of H₂SO₄ (98 %). The mixture was heated at 60°C for 5 hours. Then, it was poured into a solution saturated with NaHCO₃ and extracted with methylene chloride. The organic phase was dried (Na₂SO₄) and evaporated to give 12.3 g of 17 α -hydroxy-6,6-dimethyl-3,20-dioxo-19-nor-pregna-4-ene (yield 96.3 %), mp : 172°C.

¹H-NMR (CDCl₃, δ) : 0.79 (s, 3H) ; 1.15 (s, 6H) ; 2.09 (s, 3H) ; 5.97 (s, 1H).

To a solution of this compound (12.3 g, 35.7 mmol.) in acetic acid (120 mL) and acetic anhydride (70 mL) was added para-toluenesulfonic acid (2.5 g, 13.2 mmol.). The mixture was stirred for 12 hours at room temperature. After completion of the reaction, the excess of anhydride was decomposed by water. The mixture was extracted with methylene chloride and washed with a 1N aqueous NaOH solution. The organic phase was dried (Na₂SO₄) and concentrated. The residue was flash-chromatographed using toluene/ethyl acetate as eluting solvent and recrystallized in diisopropyl oxide (yield : 7 g, 50.81 %), mp : 200°C.

¹H-NMR (CDCl₃, δ) : 0.71 (s, 3H) ; 1.18 (s, 6H) ; 2.05 (s, 3H) ; 2.11 (s, 3H) ; 5.99 (s, 1H).

EXAMPLES 2 AND 3 : 17 α -acetoxy-6 β -ethyl-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene (5.a) and 17 α -acetoxy-6 β -propyl-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene (5.b)

Starting from compound 3 using the process described for compound 5 but replacing the methyl magnesium bromide by ethyl or propyl magnesium bromide the following compounds were obtained : 17 α -acetoxy-6 β -ethyl-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene, mp : 160°C (example 2).

¹H-NMR (CDCl₃, δ) : 0.7 (s, 3H) ; 0.72 (t, 3H) ; 1.08 (s, 3H) ; 2.05 (s, 3H) ; 2.11 (s, 3H) ; 5.95 (s, 1H);

and 17 α -acetoxy-6 β -propyl-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene (example 3).

EXAMPLE 4 : 17 α -acetoxy-1 α ,2 α -methylene-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene (10)

A₁/ 17 α -acetoxy-6 α -methyl-3,20-dioxo-19-nor-pregnane (6)

To a solution of 17 α -acetoxy-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene (10 g, 26.84 mmol.) in dioxane (100 mL) and water (100 mL) containing NaHCO₃ (14.65 g, 174.46 mmol.) was added sodium dithionite (7.9 g, 38.5 mmol.) and the reaction mixture was stirred at 50°C for 1 hour, during which time additional sodium dithionite was added in three portions of 7.9 g each. The reaction mixture was cooled to room temperature and cold water was added until the solution became clear. Thereafter, the solution was extracted with diethyl ether, dried (Na₂SO₄), concentrated in vacuo and flash-chromatographed (toluene/ethyl acetate) to give 2 g of compound 6 (yield : 20 %), mp : 202°C.

¹H-NMR (CDCl₃, δ) : 0.65 (s, 3H) ; 0.86 (d, 3H) ; 2.03 (s, 3H) ; 2.09 (s, 3H) ; 2.31 (m, 3H) ; 2.62 (m, 1H) ; 2.90 (m, 1H).

B₁/ 17 α -acetoxy-6 α -methyl-3,20-dioxo-19-nor-pregna-1-ene (7)

A mixture of compound 6 (20 g, 53.40 mmol.) and Pd(OAc)₂ (14.38 g, 64.05 mmol.) in acetonitrile (300 mL) was refluxed for 8 hours. After cooling, the palladium was filtered and the solvent evaporated. The residue was flash-chromatographed on silica gel using toluene/ethyl acetate (8/2) as eluting solvent to give 7 g of compound 7 (yield : 35 %), mp : 186-188°C.

¹H-NMR (CDCl₃, δ) : 0.69 (s, 3H) ; 0.93 (d, 3H) ; 2.07 (s, 3H) ; 2.12 (s, 3H) ; 2.76 (d, 1H) ; 2.94 (m, 1H) ; 6.02 (dd, 1H) ; 7.11 (dd, 1H).

C₁/ 17 α -acetoxy-1 α ,2 α -methylene-6 α -methyl-3,20-dioxo-19-nor-pregnane (9)

To a stirred suspension of trimethylsulfoxonium iodide (7.68 g, 34.91 mmol.) in dimethyl sulfoxide (50 mL) was added sodium hydride in oil (60 %) (1.53 g, 38.2 mmol.). The mixture was stirred at 25°C for 1 hour, and then compound 7 (2.97 g, 7.98 mmol.) was added. After 3 hours, the reaction mixture was poured in water. Collection of the resulting solid by filtration and flash-chromatography on silica gel using toluene/ethyl acetate as eluting solvent gave 1 g of compound 9 (yield : 33 %), mp : 204°C.

¹H-NMR (CDCl₃, δ) : 0.68 (s, 3H) ; 0.84 (d, 3H) ; 2.02 (s, 3H) ; 2.12 (s, 3H) ; 2.52 (dd, 1H) ; 2.92 (m, 1H).

D₁/ 17 α -acetoxy-1 α ,2 α -methylene-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene

To a solution of compound 9 (4 g, 10.35 mmol.) in tetrahydrofuran (80 mL) was added portionwise pyridinium tribromide (3.83 g, 11.38 mmol.). After 30 min. the mixture was filtered, evaporated and the residue extracted with methylene chloride, washed with water and dried (Na₂SO₄). Evaporation of the solvent gave 5 g of a brown oil to which dimethyl formamide (80 mL), Li₂CO₃ (1.53 g, 20.70 mmol.) and LiBr (0.90 g, 10.35 mmol.) were added. The mixture was heated at 140°C for 1 hour. After cooling the salts were removed by filtration and the solvent concentrated under reduced pressure. The residue was extracted with methylene chloride, washed with water and dried on Na₂SO₄. Flash-chromatography on silica gel using toluene/ethyl acetate as eluting solvent gave 2 g of the title compound (yield : 50 %), mp : 210°C.

¹H NMR (CDCl₃, δ) : 0.71 (s, 3H) ; 1.09 (d, 3H) ; 2.04 (s, 3H) ; 2.12 (s, 3H) ; 2.42 (m, 1H) ; 2.84 (m, 1H) ; 5.65 (s, 1H).

A₂/ Alternatively, compound 10 can also be prepared from 17 α -acetoxy-6 α -methyl-3,20-dioxo-19-nor-5 β -pregnane obtained from hydrogenation of 17 α -acetoxy-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene in acetic acid using Pd(OH)₂ as catalyst.

B₂/ Then, to a cooled solution of the resulting compound (20 g, 53 mmol.) in THF (200 mL) was added 17.1 g (53 mmol.) of pyridinium tribromide. After 2 hours the mixture was filtered, poured on iced water and extracted with methylene chloride. Evaporation of the solvent gave 23.8 g (yield : 98.3 %) of crude 17 α -acetoxy-2 α -bromo-6 α -methyl-3,20-dioxo-19-nor-5 β -pregnane which was dehydrobrominated following the conditions described above in step D₁ to give 15.9 g (yield: 80 %) of 17 α -acetoxy-6 α -methyl-3,20-dioxo-19-nor-5 β -pregna-1-ene (7.a), mp: 184°C.

¹H-NMR (CDCl₃, δ) : 0.69 (s, 3H) ; 0.9 (d, 3H) ; 2.02 (s, 3H) ; 2.1 (s, 3H) ; 2.9 (m, 1H) ; 6.02 (d, 1H).

C₂/ 17 α -acetoxy-3 α -hydroxy-6 α -methyl-20-oxo-19-nor-5 β -H-pregna-1-ene (8.a)

To 10 g (27 mmol.) of the compound obtained in step B₂ and 12 g of cerium chloride heptahydrate in methanol (200 mL) cooled to 0°C were added, portionwise, 2.5 g (54 mmol.) of sodium borohydride. Then, the mixture was stirred for 1 hour at room temperature, poured on iced water and the precipitate collected by filtration, dried and recrystallized from diisopropoxide to give 3.6 g of 8.a (yield: 35.6 %), mp : 211°C.

¹H-NMR (CDCl₃, δ) : 0.65 (s, 3H) ; 0.92 (d, 3H) ; 2.0 (s, 3H) ; 2.1 (s, 3H) ; 2.9 (m, 1H) ; 4.32 (m, 1H) ; 5.64 (d, 1H) ; 5.96 (dd, 1H).

D₂/ 17 α -acetoxy-1 α ,2 α -methylene-6 α -methyl-3,20-dioxo-19-nor-5 β -pregnane (9.a)

To 3 g (80 mmol.) of compound 8.a in dichloroethane (200 mL) at -25°C were added dropwise 40 mL of a 1N solution of diethylzinc in hexane followed by 6.45 mL of diiodomethane. After 1 night at room temperature, the white mixture was poured in a solution of ammonium chloride and extracted with methylene chloride. Evaporation of the solvent gave a residue which was flash-chromatographed on silica gel using toluene/ethyl acetate as eluting solvent to give 1.43 g of the 3 α -hydroxy-1 α ,2 α -methylene derivative.

¹H-NMR (CDCl₃, δ) : 0.4 (m, 2H) ; 0.68 (s, 3H) ; 0.85 (d, 3H) ; 2.05 (s, 3H) ; 2.16 (s, 3H) ; 2.9 (m, 1H) ; 4.13 (m, 1H).

Oxidation of the 3 α -hydroxy-1 α ,2 α -methylene derivative in acetone with Jones' reagent gave 1 g of 9.a (70 % yield) which was converted to 10 by the same procedure than that described in step D₁.

EXAMPLE 5 : 17 α -acetoxy-1 β ,2 β -methylene-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene (10.a)**A/ 17 α -acetoxy-6 α -methyl-3,20-dioxo-19-nor-5 β -pregnane (6.a)**

Compound 1 (20 g, 53.69 mmol.) in methanol (200 mL) containing acetic acid (5 mL) and 20 % Pd(OH)₂ (200 mg) on charcoal were hydrogenated under 1 atm. H₂. Filtration of the catalyst and removal of the solvent followed by crystallization in ethyl acetate gave 12.06 g of compound 6.a (yield: 60 %), mp : 204°C.

¹H-NMR (CDCl₃, δ) : 0.63 (s, 3H) ; 0.80 (d, 3H) ; 2.01 (s, 3H) ; 2.10 (s, 3H) ; 2.91 (m, 1H)

B/ 17 α -acetoxy-6 α -methyl-3,20-dioxo-19-nor-5 β -pregna-1-ene (7.a)

Compound 7.a was prepared in 30 % yield following the procedure described in example 4, step B₂, mp : 184°C.

¹H-NMR (CDCl₃, δ) : 0.68 (s, 3H) ; 0.92 (d, 3H) ; 2.03 (s, 3H) ; 2.09 (s, 3H) ; 2.92 (m, 1H) ; 6.03 (d, 1H) ; 7.16 (dd, 1H).

C/ 17 α -acetoxy-1 β ,2 β -methylene-6 α -methyl-3,20-dioxo-19-nor-5 β -pregnane (9.b)

Compound 9.b was prepared in 30 % yield following the procedure described in example 4, steps C₁ and D₁, mp : 174-176°C.

¹H-NMR (CDCl₃, δ) : 0.61 (s, 3H) ; 0.79 (d, 3H) ; 2.01 (s, 3H) ; 2.11 (s, 3H) ; 2.88 (m, 1H).

D/ 17 α -acetoxy-1 β ,2 β -methylene-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene

This compound was prepared in 19 % yield following the procedure described in example 4, step D₁, mp : 247°C.

IR (KBr, cm⁻¹) : 1730 ν C = O ; 1720 ν C = O ; 1644 ν C = O ; 1458 ν C = C. ¹H-NMR (CDCl₃, δ) : 0.59 (s, 3H) ; 0.94 (d, 3H) ; 1.95 (s, 3H) ; 2.00 (s, 3H) ; 2.37 (d, 1H) ; 2.82 (m, 1H) ; 5.52 (s, 1H)

EXAMPLES 6 AND 7 : 17 α -acetoxy-1 β ,2 β -methylene-3E-hydroxyimino-6 α -methyl-20-oxo- 19-nor- pregna- 4-ene (11) and 17 α -acetoxy-1 β ,2 β -methylene-3Z-hydroxyimino-6 α -methyl-20-oxo- 19-nor- pregna-4-ene (11.a)

To a solution of compound 10.a (1.24 g, 3.25 mmol.) in dioxane (50 mL) were added successively hydroxylamine hydrochloride (0.45 g, 6.46 mmol.) and pyridine (3.1 mL).

The mixture was heated to reflux for 1.5 hour. Then, the reaction mixture was poured into iced water and acidified with a 1N HCl solution. Extraction with methylene chloride and evaporation of the solvent gave 1.29 g of a crude product which was flash-chromatographed using toluene/ethyl acetate as eluting solvent.

The first product eluted was the E isomer and crystallized from ethanol (0.3 g, yield : 28.8 %), mp : 172°C (example 6).

¹H-NMR (CDCl₃, δ) : 0.5 (q, 1H) ; 0.65 (s, 3H) ; 1.02-1.04 (d, 3H) ; 2.05 (s, 3H) ; 2.12 (s, 3H) ; 2.95 (m, 2H) ; 5.62 (s, 1H).

The second product eluted was the Z isomer and it was crystallised from a mixture of absolute ethanol and diisopropyl ether (0.080 g, yield : 7.7 %), mp: 168°C (example 7).

¹H-NMR (CDCl₃, δ) : 0.681 (s, 3H) ; 1.08-1.1 (d, 3H) ; 2.05 (s, 3H) ; 2.12 (s, 3H) ; 2.95 (m, 1H) ; 6.32 (s, 1H).

EXAMPLE 8 : 17 α -acetoxy-2 α ,6 α -dimethyl-3,20-dioxo-19-nor-pregna-4-ene (10.b)

A solution of 20,20-ethanedioxy-17 α -hydroxy-6 α -methyl-19-nor-pregna-4-ene (prepared from compound 5, R₃=CH₃, R₅=H, R₆=H, R₄=H) (10 g, 26.7 mmol.), sodium methylate (8.25 g, 152.2 mmol.) and ethyl formate (12.71 g, 171.6 mmol.) was stirred at room temperature for 4 hours. Then, the precipitate was filtered, washed with diethoxyide to yield 11 g of the crude 2-hydroxymethylene sodium salt derivative which was used without further purification.

To this compound (11 g) in acetone (180 mL) were added potassium carbonate (13.5 g, 98 mmol.) and methyl iodide (46.4 g, 326.8 mmol.) and the mixture was stirred at room temperature for 12 hours. After filtration, the organic solution was poured into a solution of 1N NaOH, extracted with methylene chloride, dried (Na₂SO₄) and concentrated

in vacuo to give a crude product (12.70 g) to which was added methanol (70 mL) and a solution of 6.66 g (166.5 mmol.) of sodium hydroxide in water (6.6 mL) and the solution was refluxed for 5 hours. After cooling, the mixture was acidified to pH = 1 with a solution of 1N HCl and then, poured into water. The precipitate was collected, washed with water and dried. Flash-chromatography on silica gel (toluene/ethyl acetate) gave 4.10 g of the 17 α -hydroxy derivative of the title compound (yield : 40 %).

¹H-NMR (CDCl₃, δ) : 0.78 (s, 3H) ; 1.10 (d, 6H) ; 2.27 (s, 3H) ; 2.68 (t, 1H) ; 2.83 (s, 1H) ; 5.87 (s, 1H).

It was converted to its acetyl derivative following the procedure described for compound 6.a in 30% yield, mp : 144°C.

¹H-NMR (CDCl₃, δ) : 0.7 (s, 3H) ; 1.13 (d, 6H) ; 2.06 (s, 3H) ; 2.12 (s, 3H) ; 2.95 (t, 1H) ; 5.88 (bs, 1H).

EXAMPLE 9 : 17 α -acetoxy-1 α ,6 α -dimethyl-3,20-dioxo-19-nor-pregn-4-ene (10.c)

A/ 17 α -acetoxy-1 α ,6 α -dimethyl-3,20-dioxo-19-nor-pregnane (12)

To a suspension of copper chloride (1.59 g, 16.11 mmol.) in tetrahydrofuran (400 mL) at 0°C under N₂ was added slowly methyl lithium (1.6 N) in diethyloxide (28.76 mL, 32.21 mmol.). After 1 hour, a solution of compound 7 (5 g, 13.42 mmol.) in tetrahydrofuran (40 mL) was added to the mixture at 0°C. After 6 hours, a saturated solution of ammonium chloride was carefully added dropwise over 10 min. This mixture was stirred for 15 min., then extracted with dichloromethane. The organic layer was dried (MgSO₄) and concentrated. The resulting crude product was flash-chromatographed (toluene/ethyl acetate) to give 3 g of 12 (yield : 57 %), mp : 183°C.

¹H-NMR (CDCl₃, δ) : 0.66 (s, 3H) ; 0.81 (d, 3H) ; 0.86 (d, 3H) ; 2.01 (s, 3H) ; 2.10 (s, 3H) ; 2.90 (t, 1H).

B/ Using the same procedure than that described for the preparation of compound 10 from compound 9, compound 10.c was obtained in 35% yield, mp : 209°C

¹H-NMR (CDCl₃, δ) : 0.81 (s, 3H) ; 0.90 (d, 3H) ; 1.15 (d, 3H) ; 2.06 (s, 3H) ; 2.12 (s, 3H) ; 2.95 (t, 1H) ; 5.95 (s, 1H).

EXAMPLE 10: 17 α -acetoxy-1 β ,6 α -dimethyl-3,20-dioxo-19-nor-pregna-4-ene (10.d)

A/ 17 α -acetoxy-1 β ,6 α -dimethyl-3,20-dioxo-19-nor-5 β -pregnane (12.a)

Compound 12.a was prepared in 60 % yield following the procedure described for compound 12, mp : 142°C.

¹H-NMR (CDCl₃, δ) : 0.66 (s, 3H) ; 0.83 (d, 3H) ; 0.98 (d, 3H) ; 2.06 (s, 3H) ; 2.14 (s, 3H) ; 2.92 (t, 1H).

B/ Using the same procedure than that described for the preparation of compound 10 from compound 9, compound 10.d was obtained in 40 % yield, mp: 187°C

¹H-NMR (CDCl₃, δ) : 0.69 (s, 3H) ; 1.06 (d, 3H) ; 1.09 (d, 3H) ; 2.06 (s, 3H) ; 2.12 (s, 3H) ; 2.97 (m, 1H) ; 5.77 (s, 1H).

The following examples illustrate the preparation of representative pharmaceutical formulations containing a compound of formula (I) :

For oral administration**EXAMPLE 11**

5 *Tablets with delayed release.*

Unit formulation for various dosages :

10

15

20

Compound of formula (I)	0.50 to 10.00 mg
Aerosil® 200	0.37 to 0.50 mg
Precirol® ATO 5	1.85 to 2.25 mg
Methocel® E4	55.00 to 70.00 mg
Avicel PH® 101	10.00 to 20.00 mg
Lactose qs for 1 tablet of	185.00 to 200.00 mg

EXAMPLE 12

Fast release tablets.

25

Unit formulation for various dosages :

30

35

Compound of formula (I)	0.50 to 10.00 mg
Aerosil® 200	0.37 to 0.50 mg
Precirol® ATO 5	1.85 to 2.50 mg
Avicel® PH 102	50.00 to 70.00 mg
Explotab® or polyplasdone® XL	5.00 to 25.00 mg
Lactose qs for 1 tablet of	185.00 to 200.00 mg

40

EXAMPLE 13

Tablets.

45

Unit formulation for various dosages :

50

55

Compound of formula (I)	0.50 to 10.00 mg
Aerosil® 200	0.30 to 0.50 mg
Compritol®	1.50 to 3.00 mg
Avicel® PH 101	55.00 to 70.00 mg
Lactose qs for 1 tablet of	185.00 to 200.00 mg

Capsules.

Unit formulation for various dosages :

Compound of formula (I)	0.50 to 10.00 mg
Oleic acid qs for 1 capsule	250.00 to 260.00 mg
Coating : gelatine, preservatives, glycerol	

For vaginal administration**EXAMPLE 14***Vaginal gynaecologic capsule.*

Unit formulation for a capsule :

Compound of formula (I)	0.50 to 15.00 mg
Vaseline	150.00 to 200.00 mg
Sorbitol sesquioleate	150.00 to 200.00 mg
Synthetic perhydrosqualene qs for 1 capsule of 1.85 g	
Coating : gelatine, glycerol, preservatives for a soft capsule weighing 2.55 g	

EXAMPLE 15*Vaginal suppository.*

Unit formulation for a suppository :

Compound of formula (I)	0.50 to 15.00 mg
Witepsol® H35 or H37 qs for a suppository of 3.00 g	

EXAMPLE 16*Slow release vaginal suppository.*

Unit formulation for a suppository of 3.00 g :

Compound of formula (I)	0.50 to 30.00 mg
Witepsol® H19 or H35	1.00 to 1.30 g
Suppocire® BM or NAI50	1.00 to 1.50 g
Precirol®	0.00 to 0.20 g

For cutaneous or gynaecologic use

EXAMPLE 17

5 Bioadhesive gel for cutaneous or gynaecologic use.

Formula for 100 g :

Compound of formula (I)	0.10 to 1.00 g
Polyethylene glycol	0.00 to 6.00 g
Transcutol®	0.00 to 6.00 g
Carboxypolyvinyl polymer	0.50 to 1.00 g
Preservatives	0.30 mg
Triethanolamine qs pH 6.5	
Purified water qs for 100 g	

EXAMPLE 18

Gel for cutaneous use.

Formula for 100 g :

Compound of formula (I)	0.10 to 2.00 g
Polyethylene glycol or Transcutol®	1.00 to 4.00 g
Ethyl alcohol	20.00 to 40.00 g
Carboxypolyvinyl polymer	0.50 to 2.00 g
Triethanolamine qs pH 6.5	
Purified water qs for 100 g	

EXAMPLE 19

Patches.

Content of the reservoir or matrix.

45 Preparation for 100 g

Compound of formula (I)	0.25 to 20.00 mg
Enhancer*	0.20 to 0.50 g
Suspending agent (HPMC** or Aerosil®)	0.10 to 1.00 g
Ethyl alcohol or silicone oil qs for 100 g	

* enhancer : isopropyl palmitate, propyleneglycol, menthol, azone, N,N-dimethylacetamide, mono- or disubstituted pyrrolidone derivatives ;

** HPMC : hydroxypropylmethylcellulose

For percutaneous administration**EXAMPLE 20***Implants.*

Formulation for 100 g of material to be extruded :

Compound of formula (I)	1.00 to 5.00 g
Polymers (EVA, polyorthocarbonates, silicone-based polymers) qs for 100 g	
The temperature of the mixture shall not exceed 150°C in order not to impair the active ingredient.	

Implants with reservoir.

The implant is a sealed silicone tubing of 2.5 to 3.5 cm long, 0.4 to 0.8 mm thick and 1.40 to 2mm in diameter. The preparation is formulated as a suspension as follows : For 100 g of suspension.

Compound of formula (I)	30.00 to 50.00 g
Suspending agent qs for 100 g	
50 mg of the suspension for one implant.	

EXAMPLE 21*Injectable depot.*

Unit formulation for a flask of 5 ml.

Compound of formula (I)	10.00 to 50.000 mg
Polyethylene glycol 4000	100.00 to 200.000 mg
Preservatives	0.006 mg
Sodium chloride and citrate	0.150 mg
Distilled water for injection qs for 5.00 ml	

EXAMPLE 22*Injectable suspension.*

Unit formulation for a 2 ml ampoule :

Compound of formula (I)	5.00 to 10.00 mg
-------------------------	------------------

Suspension solution :

Polysorbate® 80	0.015 g
Sodium carboxymethylcellulose	0.010 g
Sodium chloride	0.010 g
Purified water for injection qs for 2.00 ml	

EXAMPLE 23

Intra-uterine device with reservoir.

- 5 Device with a silicone reservoir 2.5 to 3.5 cm long and 0.4 to 0.8 mm thick. The preparation is formulated as a suspension as follows :
For 100 g of suspension.

10	Compound of formula (I)	0.60 to 1.00 g
	suspended to :	
	Suspending agent (Aerosil® or HPMC)	0.50 g
15	Synthetic perhydrogenalene qs for 100 g	

EXAMPLE 24

Bioadhesive gynaecological foam.

- 20 Formula for a dispenser of 50 g and a spray valve (2 ml)

25	Compound of formula (I)	0.10 to 0.25 g
	Carboxypolyvinyl polymer	0.50 to 1.00 g
	Isobutane	5.00 to 10.00 g
30	Excipient base F25/1 qs for 50.00 g	
	Shake the suspension before use. Dispensed dosage from 2.00 to 10.00 mg	

- 35 **For nasal administration**

EXAMPLE 25

Nasal suspension.

- 40 Formulation for 100 g of suspension :

45	Compound of formula (I)	5.00 to 50.00 mg
	Aerosil® PH 101	10.00 to 20.00 mg
	Sodium carboxymethylcellulose	5.00 to 50.00 mg
	Phenylethyl alcohol	2.00 to 10.00 mg
50	Polysorbate® 80	10.00 to 20.00 mg
	Purified water qs for 100 g	
55	Shake the suspension before use Dispensed dosage from 0.5 to 2.5 mg	

For ophtalmic administration

EXAMPLE 26

5 *Ophthalmic solution (collyrium).*

Formulation for 100 g of solution. Container of 5 ml with glass droppers :

Compound of formula (I)	0.50 to 1.00 g
Glycerol	5.00 g
Polyvidone or sodium chloride	0.50 to 0.90 g
Sorbitol	4.00 g
Preservatives (benzalkonium chloride or Cetrimide®)	0.01 g
EDTA	0.01 g
Distilled water qs for 100 g	
The solution is a sterile aqueous solution ; it may contain stabilisers and antimicrobial agents. The recommended dose is one drop four times daily.	

EXAMPLE 27

Ophthalmic gel.

Formulation for 100 g of gel. Container : collapsible tube

Compound of formula (I)	0.50 to 2.00 g
Cetrimide®	0.01 g
Sorbitol	4.00 g
EDTA	0.01 g
Carboxypolyvinyl polymer (Carbopol® 971)	0.14 to 0.20 g
Sodium hydroxyde 10 % qs pH 6.5	
Purified water qs for 100 g.	
The sterile aqueous gel is packed in collapsible tubes. The recommended dose is one drop one or two times daily.	

Typical examples of the compounds of formula (I) provided by this invention include :

- .17 α -acetoxy-6,6-dimethyl-3,20-dioxo-19-nor-pregna-4-ene
- .17 α -acetoxy-6 β -ethyl-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene
- .17 α -acetoxy-6 β -propyl-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene
- .17 α -acetoxy-1 α ,2 α -methylene-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene
- .17 α -acetoxy-1 β ,2 β -methylene-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene
- .17 α -acetoxy-1 β ,2 β -methylene-3E-hydroxyimino-6 α -methyl-20-oxo-19-nor-pregna-4-ene
- .17 α -acetoxy-1 β ,2 β -methylene-3Z-hydroxyimino-6 α -methyl-20-oxo-19-nor-pregna-4-ene
- .17 α -acetoxy-2 α ,6 α -dimethyl-3,20-dioxo-19-nor-pregna-4-ene
- .17 α -acetoxy-1 α ,6 α -dimethyl-3,20-dioxo-19-nor-pregna-4-ene
- .17 α -acetoxy-1 β ,6 α -dimethyl-3,20-dioxo-19-nor-pregna-4-ene

Q

- 5



①

15

20

X is oxygen or an hydroxyimino group,

25

30

- 35

- 40

- 45

- 50

- 55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 40 0146

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Y	FR-A-2 111 097 (CIBA-GEIGY A.G.) 2 June 1972 * the whole document *	1-14	C07J7/00 A61K31/57 C07J53/00 C07J41/00
Y	DE-A-20 48 231 (CIBA-GEIGY A.G.) 29 April 1971 * the whole document *	1-14	//C07J71/00, C07J21/00
Y	US-A-3 759 962 (ANNER G ET AL) 18 September 1973 * the whole document *	1-14	
Y	EXPERIENTIA, vol. 23, no. 10, 1967, BASEL CH, pages 794-796, XP002005533 L. A. MITSCHER ET AL: "1,2-Methylen-19-nor-17.alpha.-acetoxy-progesteron" * page 796, column 1, line 6 - line 10 *	1-14	
Y	DE-B-10 87 127 (SCHERING A.G.) 18 August 1960 * column 1, paragraph 2; example 3 *	1-14	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
Y	DE-A-15 93 524 (SCHERING A.G.) 13 August 1970 * page 1, paragraph 1; examples 1,2B *	1-14	C07J A61K
Y	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 78, no. 11, 8 June 1956, DC US, pages 2479-2481, XP002005534 C. DJERASSI ET AL: "1-Methyl-19-norprogesterone and 1-Methyl-19-nor-17.alpha.-hydroxyprogesterone" * the whole document *	1-14	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 13 June 1996	Examiner Watchorn, P
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 01.82 (P04C01)




European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 40 0146

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Y	FR-A-1 525 916 (SCHERING A.G.) 30 October 1968 * whole document, particularly page 2, table *	1-14	
Y	FR-A-1 405 214 (SOCIÉTÉ DES USINES CHIMIQUES RHÔNE-POULENC) 19 November 1965 * page 4, column 1, paragraph 3; example 38 *	1-14	
Y	US-A-3 835 160 (TANABE M) 10 September 1974 * column 11, line 3 - line 11; example 29 *	1-14	
Y	US-A-3 891 677 (TANABE MASATO) 24 June 1975 * column 7, line 1 - line 9; example 3 *	1-14	
Y	EP-A-0 153 270 (SCHERING AG) 28 August 1985 * the whole document *	1-14	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
Place of search THE HAGUE		Date of completion of the search 13 June 1996	Examiner Watchorn, P
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.02 (P04C01)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 785 211 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
23.07.1997 Bulletin 1997/30

(51) Int. Cl.⁶: **C07J 7/00**, A61K 31/57,
C07J 53/00, C07J 41/00
// C07J13/00, C07J17/00

(21) Application number: **96400145.7**

(22) Date of filing: **22.01.1996**

(84) Designated Contracting States:
FR

(71) Applicant: **LABORATOIRE THERAMEX**
98000 Monaco (MC)


(72) Inventors:
• **Maillos, Philippe**
de St-Augustin, F-06200 Nice (FR)
• **Verdan, Christina**
F-06000 Nice (FR)

• **Delansorne, Rémi**
F-06000 Nice (FR)
• **Paris, Jacques**
F-06100 Nice (FR)
• **Pascal, Jean-Claude**
F-06200 Villefranche sur Mer (FR)

(74) Representative: **Gillard, Marie-Louise**
Cabinet Beau de Loménie
158, rue de l'Université
75340 Paris Cédex 07 (FR)

(54) **New substituted 19-nor-pregnane derivatives**

(57) The invention relates to compounds of the formula :



wherein :

each of R_1 and R_2 is hydrogen or a (C_1-C_6) alkyl, R_1 and R_2 being not simultaneously hydrogen ;

R_3 is hydrogen, a (C_1-C_6) alkyl or a (C_1-C_6) alkoxy ;

R_4 is hydrogen, a (C_1-C_6) alkyl or a group $-COR_6$ where R_6 is a (C_1-C_6) alkyl ;

R_5 is hydrogen or a (C_1-C_6) alkyl ;

n is zero or one ;

X is oxygen or an hydroxyimino group ; and

the dotted line may represent a double bond ; provided that when $n = 0$, R_3 is hydrogen only if both R_1 and R_2 are a (C_1-C_6) alkyl ;

and to pharmaceutical compositions containing them.

These compounds are potent progestogens which are devoid of residual androgenic activity.

EP 0 785 211 A1


THIS PAGE BLANK (USPTO)

Description

The invention relates to substituted 19-nor-pregnane derivatives, methods of making these compounds and pharmaceutical compositions containing these compounds.


The compounds of this invention have excellent progestative properties while being devoid of residual androgenic activity.

Various substituted 19-nor pregnane derivatives having progestative properties have been described in the literature. For example, GB-A-1 104 968 describes 3-oximino steroids having the formula :



in which R is hydrogen, methyl, ethyl, chlorine, bromine or fluorine ; R' is hydrogen or (C₂-C₁₂)alkanoyl and R'' is hydrogen or methyl ; said compounds being prepared from the 3-oxo derivatives.

DE-A-2 148 261 describes a method of preparing 6 α -methyl-19-nor-pregnenes of the formula :



in which R₁ is hydrogen or methyl and R₂ is (C₁-C₉)alkyl.

BE 757 285 relates to pharmaceuticals containing 3,20-dioxo-6 α -methyl-17 α -acetoxy-19-nor- Δ^4 -pregnene.


In addition, 15,16-methylenesteroids, among which 3-O- Δ^4 -19-nor-17 β -Ac-17 α -OH-15 α ,16 α -methyleneandrostane and 3-O- Δ^4 -19-nor-17 β -Ac-17 α -OAc-15 α ,16 α -methyleneandrostane, are described in Chem. Ber. 107, 128-134 (1974).

19-nor progesterone derivatives such as those described above usually exhibit however androgenic side effects.

The Applicant has now found that 19-nor pregnane derivatives which possess at least two substituents in position 6-, 7-, 15- and/or 15,16- display excellent progestative activity and are devoid of residual androgenic activity.

A first aspect of this invention thus encompasses compounds having the structure represented by the following general formula (I):

THIS PAGE BLANK (USPTO)



wherein :

each of R_1 and R_2 is hydrogen or a (C_1-C_6) alkyl, R_1 and R_2 being not simultaneously hydrogen ;

R_3 is hydrogen, a (C_1-C_6) alkyl or a (C_1-C_6) alkoxy ;

R_4 is hydrogen, a (C_1-C_6) alkyl or a group $-COR_6$ where R_6 is a (C_1-C_6) alkyl ;

R_5 is hydrogen or a (C_1-C_6) alkyl ;

n is zero or one ;

X is oxygen or an hydroxyimino group ; and

the dotted line may represent a double bond ; provided that when $n = 0$, R_3 is hydrogen only if both R_1 and R_2 are a (C_1-C_6) alkyl.

As used herein, the term "alkyl" means a branched or unbranched saturated hydrocarbon radical, such as methyl, ethyl, propyl ; isopropyl, butyl, isobutyl, t-butyl, pentyl and hexyl.


As used herein the term "alkoxy" means the group $-OR$ wherein R is alkyl as defined above. Examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentoxy and hexyloxy.

As used herein the group $-COR_6$ wherein R_6 is alkyl as defined above includes, for example, acetyl, propionyl, butyryl, isobutyryl, t-butyryl, valeryl and hexanoyl.


Among the compounds of formula (I), those wherein R_1 and R_3 are a (C_1-C_6) alkyl, R_2 and R_5 are hydrogen, R_4 is a group $-COR_6$, particularly an acetyl group, and n is zero are preferred. Also preferred are the compounds of formula (I) wherein R_1 is a (C_1-C_6) alkyl, R_3 and R_5 are hydrogen, R_4 is a group $-COR_6$, particularly an acetyl group and n is one, those where X is oxygen being especially preferred. Further preferred are the compounds of formula (I) wherein R_1 and R_4 are a (C_1-C_6) alkyl, R_2 , R_3 and R_5 are hydrogen and n is one, those where X is oxygen being especially preferred. Other preferred compounds of formula (I) include those wherein R_1 and R_2 are a (C_1-C_6) alkyl, R_3 and R_5 are hydrogen, R_4 is a group $-COR_6$, particularly an acetyl group, and n is zero.

Another aspect of this invention relates to a method of preparing the compounds of formula (I) : these compounds can be made following the Reaction Scheme below wherein R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , n and X have the same meaning as set forth above.

THIS PAGE BLANK (USPTO)

REACTION
SCHEME

THIS PAGE BLANK (USPTO)

REACTION
SCHEME

Compounds of formula 1.I are prepared according to procedures described by B.M. Trost et al., J. Am. Chem. Soc. 1976, 98(16), 4887-902, or by J.R. Bull et al., J. Chem. Res. Synop. 1979, (7), 224-5.

Referring to reaction scheme in step 1, compounds of formula 2.I ($n = 0$, $R_3 = \text{alkyl}$) are prepared using the procedures of M.B. Groën et al., Rec. Trav. Chim. Pays-Bas 1979, 98 (4), 239-49, or R.V. Coombs (US patent 3,766,224).

THIS PAGE BLANK (USPTO)

Compounds of formula 2.I ($n = 1$, $R_3 = H$) are prepared by a Corey reaction of a compound of formula 1.I with a dimethylsulfoxonium methylide produced by the reaction of trimethylsulfoxonium iodide with sodium hydride in tetrahydrofuran or dimethylsulfoxide. They can also be prepared by the reaction of diazomethane catalyzed by palladium or copper derivatives.

Compounds of formula 2.I ($n = 0$, $R_3 = \text{alkoxy}$) can be prepared using the procedure described by E.N. Cantrall et al., J. Org. Chem. (1964), 29, 64.

Compounds of formula 2.I are condensed with an alkyl-triphenyl-phosphonium bromide in a dimethylsulfoxide/sodium hydride mixture at a temperature from about 10°C to 40°C, preferably at 20°C.

After about 1 to 24 hours, preferably 8 to 12 hours, products of formula 3.I are separated from the reaction mixture by precipitation on water followed by crystallization in an alcohol, preferably methanol or ethanol.

Compounds of formula 3.I are oxidized by a complex of N-methyl-morpholine oxide-hydrogen peroxide catalysed by osmium tetroxide, or N-triethylamine oxide-hydrogen peroxide catalysed by osmium tetroxide in tert-butanol at a temperature from about 0°C to 40°C, preferably at 20°C for about 2 to 12 hours, preferably 6 hours. The reaction mixture is treated with a solution of sodium sulfite (Na_2SO_3) and compounds of formula 4.I are obtained by precipitation on water or flash-chromatography. Other oxidizing agents such as KMnO_4 in an acetone/water mixture can be used in this step following a process described by A.J. Fatiadi (Synthesis 1987, 85).

Compounds of formula 5.I are then dissolved in toluene to which is added 1 to 10 molar equivalents of ethylene glycol, preferably 5 molar equivalents, triethylorthoformate and a catalytic amount of p-toluenesulfonic acid. The reaction mixture is stirred at a temperature of about 20°C to 80°C, preferably 40°C, for about 2 to 8 hours, preferably 6 hours. Then, the reaction mixture is cooled and poured into iced water and extracted with a suitable organic solvent, such as toluene, diethyl ether and the like. When the solvent is removed under reduced pressure, a residue is formed which can be purified by crystallization in an alcohol by flash-chromatography to yield compounds of formula 5.I.

Compounds of formula 5.I are submitted to Birch reduction following the procedure of A.J. Birch et al., J. Chem. Soc. (1949), 2531, yielding compounds of formula 6.I.

The tertiary hydroxy group can be optionally esterified by known processes used for esterification in steroid chemistry or etherified by an alkyl halide according to conventional methods of Williamson ether synthesis such as described by B. G. Zupancic et al., Synthesis (1979), 123 or by D.R. Benedict et al., Synthesis (1979), 428-9 to give compounds of formula 7.I ($R_4 = H$, $-\text{COR}_6$ or alkyl).

The corresponding alkyl enol ethers of formula 8.I are obtained by reaction with a trialkylorthoformate, preferably triethylorthoformate in an alcohol such as methanol, ethanol, propanol or n-butanol, preferably ethanol with a catalytic amount of toluene sulfonic acid. The reaction temperature can be, for example, room temperature to the boiling temperature of the reaction mixture.

The alkyl enol ethers are reacted with a Vilsmeier-Hack formylating agent in DMF at a temperature below 0°C, preferably -10°C, giving compounds of general formula 9.I.

Sodium borohydride reduction of compounds 9.I in a mixture of DMF and CH_3OH following by dehydration with a strong mineral acid such as H_2SO_4 , HCl or HBr , preferably sulfuric acid, yield compounds of formula 10.I. Alternatively, compounds of formula 9.I can be directly converted to 12.I by a process similar to that described by D. Burn et al., Tetrahedron (1965), 21, 1619-24.

Treatment of 10.I with palladium-on-charcoal in refluxing alcohol such as methanol, ethanol or isopropanol gives, after filtration of the catalyst and crystallization in an appropriate solvent compounds of formula 11.I. Alternatively, compounds of formula 10.I can be directly converted to compounds of formula 12.I by hydrogenation. The pure isomers are obtained by crystallization or by preparative HPLC.

Reaction of compounds of formula 12.I with an excess of hydroxylamine hydrochloride in a mixture of an alcohol, preferably ethyl alcohol, or dioxane, and pyridine at a temperature between 20°C to reflux of the solvent, preferably 60°C, leads to compounds of formula 13.I. The E and Z hydroxyimino derivatives are obtained by crystallization in a suitable solvent or by flash-chromatography.

Addition of a lithium dialkyl cuprate $\text{LiCu}(\text{R}_2)_2$, or of the corresponding alkylmagnesium halide under copper catalysis (for example CuI or CuCN) to compounds of formula 11.I following by isomerisation of the double bond in acidic condition yield compounds of formula 14.I. These can be converted to 13.I by addition of hydroxylamine.

The compounds of this invention are potent progestogens which are devoid of androgenic side effects; they are therefore useful for treating a variety of gynaecological disorders related to an oestrogen/progesterone imbalance in premenopausal women, for example: abnormal uterine bleeding (oligomenorrhea, amenorrhea, functional uterine hemorrhage...), premenstrual tension, dysmenorrhea, benign breast disease, breast tumors, premenstrual complaints such as headache, depression, water retention, mastodynia or mood alteration.

Due to their pharmacological properties, in particular their potent antigonadotropic activity, they can also be used in several other indications, such as for example the inhibition of oestrogen transformation of normal endometrium to hyperplastic or malignant states, or for the inhibition of gonadotropic/gonadal secretions (for example in the treatment of endometriosis and polycystic ovary syndrome in women and of prostate diseases in men).

The invention compounds can also be used alone as contraceptive agents in both sexes, or in combination with an

THIS PAGE BLANK (USPTO)

oestrogen, such as for example oestradiol or ethinyl oestradiol, in contraceptive formulations for premenopausal women ; they can also be used alone or in combination with an oestrogen in hormonal replacement therapy for postmenopausal women.

The progestative activity of the compounds of formula (I) can be evaluated in two specific experimental models : the affinity for the progesterone receptor (PR) *in vitro*, and the endometrial transformation of the rabbit uterus *in vivo*.

Human PR are readily available in high amounts from the T47-D cell line in culture (M.B. Mockus et al., *Endocrinology*, 1982, 110 : 1564-1571). Relative binding affinities (RBA) for the human T47-D cell PR are determined as previously described (J. Botella, et al., *J. Steroid Biochem. Molec. Biol.*, 1994, 50 : 41-47) using [³H]-ORG 2058 as the labelled specific ligand (G. Fleischmann et al., *Biochim. Biophys. Acta*, 1978, 540 : 500-517) and norgestrol acetate as the non-radioactive reference progestin. Competitive incubations were performed against 2 nM of [³H]-ORG 2058 for 3 hours at 4°C with six different concentrations of non-labelled steroid, chosen between 4 and 256 nM following a 1/2ⁿ dilution scheme. Displacement curves were fitted for each experiment, and the concentration inhibiting 50% of the specific binding of [³H]-ORG 2058 was calculated for each curve (IC₅₀).

The affinity of test compounds of the invention for human PR is given in Table 1 below :

Table 1

Relative binding affinity to human T47-D cell progesterone receptor			
Progestin	IC ₅₀ ^(a) in nM	(n)	RBA
Norgestrol acetate	16.4 ± 1.3	(13)	100%
Example 1	38.0 ± 10.3	(4)	43%
Example 2	28.8 ± 5.6	(3)	57%
Example 6	21.1 ± 6.0	(4)	78%
Example 7	19.7 ± 3.0	(4)	83%
Example 8	21.1 ± 6.0	(4)	78%
Example 9	32.3 ± 5.3	(4)	51%
Example 11	25.5 ± 5.3	(3)	64%

(a) mean ± s.e.m. ;

(n) number of experiments

One specific pharmacological test has been standardized *in vivo* for the detection and quantitation of pseudogestagenic activity since the mid-30's : it is based on the property of the uterus of estrogen-primed immature female rabbits to respond to very slight amounts of progestin by a typical endometrial transformation into a densely packed and interlaced epithelial network called "dentelle". The original test schedule, which includes 6 days of estrogen priming (total subcutaneous dose of 30 µg/rabbit of estradiol benzoate) followed by 5 days of progestative treatment, was designed as early as 1930 by C. Clauberg, *Zentr. Gynäkol.* 1930, 54 : 2757-2770. The semi-quantitative scale used to grade the intensity of the microscopical appearance of the "dentelle" was set up by M.K. McPhail, *J. Physiol (London)*, 1934, 83, 145-156. This overall Clauberg-McPhail procedure has been extensively used to screen steroids for putative progestative activity *in vivo* and is still part of the basic hormonal profile of any new progestin such as norgestimate (A. Phillips et al., *Contraception*, 1987, 36, 181-192) or desogestrel (J. Van der Vies et al., *Arzneim. Forsch./Drug Res.* 1983, 33, 231-236).

The progestative potency is inversely related to the dose needed to induce a half-maximal stimulation of the "dentelle", i.e. to record a mean McPhail grade equal to 2. This ED₅₀ is deduced for the dose-response curve and expressed in total dose/rabbit/5 days. All compounds were tested for activity only following oral administration. The maximal administered dose was 0.75 mg, roughly corresponding to 5 times the ED₅₀ of norgestrol acetate, a potent orally active 19-norprogesterone-derived progestin (J. Paris et al., *Arzneim. Forsch./Drug Res.*, 1983, 33, 710-715).

The oral activity of test compounds of the invention is given in Table 2 below :

THIS PAGE BLANK (USPTO)

Table 2

Clauberg-McPhail test by oral administration		
Progestin	ED ₅₀ (mg/rabbit/5 days)	Relative activity
Example 1	> 0.750	< 18%
Example 2	0.080	165%
Example 6	> 0.750	< 18%
Example 7	0.245	54%
Example 8	0.133	99%
Example 10	0.600	22%
Example 11	0.100	132%
Nomegestrol acetate	0.132 ± 0.013 ^(a) (0.108/0.150/0.138)	100%

(a) mean ± s.e.m. of 3 different experiments in which the cited examples were tested in parallel

The residual androgenic potential is an important feature to evaluate for any new progestin, because it is highly predictive of androgenic side-effects in women. One pharmacological model of androgenic activity has been standardized to screen steroids or related compounds in immature castrated male rats, using the hypertrophy of the ventral prostate and seminal vesicles as the endpoint, following 10 daily administrations (R.I. Dorfman, in *Methods in Hormone Research*, volume 2, LONDON, Academic Press, 1962 : 275-313 ; A.G. Hilgar et D.J. Hummel, *Androgenic and Myogenic Endocrine Bioassay Data*, edited by the U.S. Department of Health, Education and Welfare, WASHINGTON D.C., 1964).

Medroxyprogesterone acetate is a 6 α -methylpregnene derivative which, besides its main progestative activity, is well-known for its weak androgenic properties (M. Tausk et J. de Visser, In *International Encyclopedia of Pharmacology and Therapeutics, Section 48 : Progesterone, Progestational Drugs and Antifertility Agents*, volume II, OXFORD, Pergamon Press, 1972 : 35-216) ; it was therefore chosen as a reference compound in the testing for residual androgenic activity of test examples according to the invention.

The compounds of examples 2 and 7 were tested for residual androgenic properties in the immature castrated male rat model by oral administration (PO), in comparison with medroxyprogesterone acetate, in two different experiments (ventral prostate and seminal vesical hypertrophy), as described above ; testosterone was used as a standard androgenic agent by subcutaneous injection (SC).

Table 3

Residual androgenic activity of the compound of example 2			
Steroid	Dose (mg/animal/day)	Ventral Prostate (mg)	Seminal Vesicle (mg)
Castrated controls	-	14.6 ± 1.4	10.4 ± 0.4
Testosterone, SC	0,05	85.1 ± 5.9**	85.9 ± 6.8**
Medroxyprogesterone acetate, PO	20	23.1 ± 1.1*	22.1 ± 1.1**
Example 2, PO	20	13.0 ± 1.1 ns	12.1 ± 0.7 ns
mean ± s.e.m. of 8 animals per group ;			

* p < 0.05 and

** p < 0.01

ns : not statistically different from controls.

THIS PAGE BLANK (USPTO)

Table 4

Residual androgenic activity of the compound of example 7			
Steroid	Dose (mg/animal/day)	Ventral Prostate (mg)	Seminal Vesicle (mg)
Castrated controls	-	12.0 \pm 0.9	12.3 \pm 0.7
Testosterone, SC	0,05	90.4 \pm 4.4***	90.3 \pm 6.3**
Medroxyprogesterone acetate, PO	20	29.1 \pm 1.4***	19.9 \pm 1.8**
Example 7, PO	20	16.5 \pm 0.9 **	13.9 \pm 0.8 ns
mean \pm s.e.m. of 8 animals per group ;			

* p < 0.05 and

** p < 0.01

ns : not statistically different from controls.

The compound of example 7 exhibits a very limited androgenic potential, which reaches statistical significance on ventral prostate weights but not on seminal vesicle weights (Table 3), and the compound of example 2 is totally devoid of any activity on the growth of male accessory sex organs, up to at least 20 mg/animal/day (Table 4). By comparison, medroxyprogesterone acetate reproducibly induces approximately twice the values obtained for the above compounds at the same dose (Tables 3 and 4).

Thus, the compounds of the present invention are excellent progestogens with no residual androgenic activity.

Thus according to another aspect, the invention relates to pharmaceutical compositions containing an effective amount of a compound of formula (I), mixed with suitable pharmaceutical excipients. Said compositions may further comprise an effective amount of an oestrogen.

Another aspect of the invention comprises a method of treating or preventing gynaecological disorders ; a method of inhibiting oestrogen transformation of endometrium ; and a method of inhibiting gonadotropic/gonadal secretions.

The compounds of this invention are administered at a therapeutically effective dosage, i.e., a dosage sufficient to provide treatment for the disease states previously described. Administration of the active compounds described herein can be via any of the accepted modes of administration for agents that serve similar utilities.

Generally, a daily dose is from 0.001 to 1 mg/kg of body weight per day of the compound of formula (I). Most conditions respond to a treatment comprising a dosage level on the order of 0.002 to 0.2 mg/kg of body weight per day. Thus, for administration to a 50 kg person, the dosage range would be about 2 mg per day, preferably between about 0.5 to 5 mg per day.

Depending on the specific disease state, administration can be via any accepted systemic route, for example, via oral route, parenteral route such as intravenous, intramuscular, subcutaneous or percutaneous route, or vaginal, ocular or nasal route, in the form of solid, semi-solid or liquid dosage forms, such as for example, tablets, suppositories, pills, capsules, powders, solutions, suspensions, cream, gel, implant, patch, pessary, aerosols, emulsions or the like, preferably in unit dosage forms suitable for simple administration of precise dosages. The compositions will include a conventional pharmaceutical carrier or vehicle and an active compound of formula (I) and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc.

If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.

The compounds of this invention are generally administered as a pharmaceutical composition which comprises a pharmaceutical vehicle in combination with a compound of formula (I). The level of the drug in a formulation can vary within the full range employed by those skilled in the art, e.g., from about 0.01 weight percent (wt%) to about 99.99 wt% of the drug based on the total formulation and about 0.01 wt% to 99.99 wt% excipient.

The preferred manner of administration, for the conditions detailed above, is oral administration using a convenient daily dosage regimen which can be adjusted according to the degree of affliction. For such oral administration, a pharmaceutically acceptable, non-toxic composition is formed by the incorporation of the compound of formula (I) in any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, gelatin, sucrose, magnesium carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain between 0.01 wt% and 99.99 wt% of the compound of formula (I).

Preferably the compositions will take the form of a sugar coated pill or tablet and thus the composition will contain,

THIS PAGE BLANK (USPTO)

along with the active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, and the like ; a disintegrant such as starch or derivatives thereof ; a lubricant such as a magnesium stearate and the like ; and a binder such as a starch, polyvinylpyrrolidone, gum acacia, gelatin, cellulose and derivatives thereof, and the like.

5 EXAMPLES

The following examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as a limitation of the scope of the invention but merely as being illustrative and representative thereof. In these examples, the following abbreviations are used :

10	MeOH :	methanol
	EtOH :	ethanol
	Ac :	acetyl
	OAc :	acetoxy
15	AcOEt :	ethyl acetate
	DMF :	dimethylformamide
	THF :	tetrahydrofuran
	Pd/C :	palladium -on- charcoal
	Pd/Al ₂ O ₃ :	palladium -on- alumina
20	DMSO :	dimethylsulfoxide
	DDQ :	2,3-dichloro-5,6-dicyanobenzoquinone
	s :	singlet
	d :	doublet
	t :	triplet
25	q :	quadruplet
	bs :	broad singlet
	dd :	doubled doublet
	m :	multiplet

30 EXAMPLE 1

17 α -acetoxy-6,15 β -dimethyl-3,20-dioxo-19-nor-pregna-4,6-diene (11.I.a : R₁ = CH₃, R₃ = CH₃, R₄ = Ac, R₅ = H, n = 0)

AV 3-methoxy-15 β -methyl-19-nor-pregna-1,3,5(10)-17(20)-tetraene (Z or E) (3.I.a : R₃ = CH₃, R₅ = H, n = 0)

35 Sodium hydride (60 % in mineral oil, 4.88 g, 122 mmol.) was added to a round-bottomed flask fitted with a magnetic stirrer bar. The sodium hydride dispersion was washed with dry hexane to remove the mineral oil and 200 mL of dry dimethylsulfoxide was added to the flask. Ethyl-triphenyl-phosphonium bromide (37.77 g, 101 mmol.) was added to the dispersion and the solution was stirred at 20°C under nitrogen for 2 hours. Then 3-methoxy-15 β -methyl-estra-1,3,5(10)-triene-17-one (2.I.a) obtained as described in "Recueil des travaux chimiques des Pays Bas" (vol 98, n°4, 1979) was added to the solution and the mixture was stirred for 22 hours at room temperature. The mixture was poured into 2 L of iced water and stirred for 1 hour, then filtered and recrystallized from ethanol to give 3.I.a (9.17 g, yield : 73 %), mp : 97°C.

¹H-NMR (CDCl₃, δ) : 0.99 (d, 3H) ; 1.02 (s, 3H) ; 1.69 (d, 3H) ; 3.70 (s, 3H) ; 6.65 (d, 1H) ; 6.75 (dd, 1H) ; 7.21 (d, 1H).

45 B/ 17 α -hydroxy-3-methoxy-15 β -methyl-20-oxo-19-nor-pregna-1,3,5(10)-triene (4.I.a : R₃ = CH₃, R₅ = H, n = 0)

A solution of osmium tetroxide in pyridine (20 g/L ; 11 mL) was added to a suspension of compound 3.I.a (9.17 g ; 29.5 mmol.) in 200 mL of 2-hydroxy-2-methylpropane. Then, a complex of N-methylmorpholine oxide-hydrogen peroxide prepared as described in Reagents for Organic Synthesis, Fieser and Fieser vol. 1, p. 690 (4.9 g, 29 mmol.) was added. The solution was stirred for 6 hours. The reaction mixture was treated with 150 mL of 0.5 % sodium sulfite, stirred for 1 hour and filtered. The filtrate was evaporated to dryness and the crude product was flash-chromatographed using toluene/ethyl acetate (95/5) as eluting solvent to give 5.7 g of 4.I.a (yield : 56 %), mp : 61°C.

IR (KBr, cm⁻¹) : 3335 ν OH ; 1687 ν C = O

55 ¹H-NMR (CDCl₃, δ) : 0.91 (s, 3H) ; 1.08 (d, 3H) ; 2.31 (s, 3H) ; 2.94 (s, 1H) ; 3.48 (d, 2H) ; 3.78 (s, 3H) ; 6.63 (d, 1H) ; 6.71 (dd, 1H) ; 7.20 (d, 1H).

C/ 20-(ethylenedioxy)-17 α -hydroxy-3-methoxy-15 β -methyl-19-nor-pregna-1,3,5 (10) triene (5.I.a : R₃ = CH₃, R₅ = H, n = 0)

p-toluenesulfonic acid (600 mg, 3.12 mmol.), compound 4.I.a (12.06 g, 35.2 mmol.), ethylene glycol (250 mL, 6.98 mol.), triethylorthoformate (50 mL, 297 mmol.) in toluene (120 mL) were stirred together for 5 hours. Precipi-

THIS PAGE BLANK (USPTO)

tation on water and extraction with toluene gave, after evaporation, a crude product which was chromatographed using a mixture of toluene/ethyl acetate (95/5) as eluting solvent to give 12 g of 5.I.a (yield: 88 %), mp : 113°C.

IR (KBr, cm^{-1}) : 3574 νOH

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.99 (s, 3H) ; 0.99 (d, 3H) ; 1.40 (s, 3H) ; 3.73 (s, 3H) ; 6.19 (dd, 1H) ; 6.51 (d, 1H) ; 7.19 (d, 1H).

D/ 17 α -hydroxy-15 β -methyl-3,20-dioxo-19-nor-pregna-4-ene (6.I.a : $\text{R}_3 = \text{CH}_3$, $\text{R}_5 = \text{H}$, $n = 0$)

Compound 5.I.a (12.36 g, 32 mmol.) was dissolved in 160 mL of dry THF and 12 mL of ethanol was added. The solution was then poured into ammoniac (250 mL) at -30°C. Lithium (2.4 g, 345 mmol.) was added portionwise at -30°C, and the dark solution was stirred at -30°C for 1 hour. Ethanol (12 mL) was added and the solution was stirred for 15 hours at room temperature. Then ammoniac was removed, methanol (250 mL) and a solution of 50 % hydrogen chloride (HCl, 100 mL) were added, followed by an extraction with dichloromethane. The organic layer was dried (Na_2SO_4) and evaporated under reduced pressure giving 10.17 g of crude 6.I.a (yield : 96 %), mp : 218°C.

UV $_{\lambda_{\text{max}}}$: 239 nm

IR (KBr, cm^{-1}) : 3439 νOH ; 1701 $\nu\text{C} = \text{O}$; 1651 $\nu\text{C} = \text{O}$ conjugated

$^1\text{H-NMR}$ (CDCl_3, δ) : 1.88 (s, 3H) ; 2.01 (d, 3H) ; 3.21 (s, 3H) ; 4.00 (s, 1H) ; 6.76 (s, 1H).

E/ 17 α -acetoxy-15 β -methyl-3,20-dioxo-19-nor-pregna-4-ene (7.I.a : $\text{R}_3 = \text{CH}_3$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 0$)

p-toluenesulfonic acid (1.2 g, 6.24 mmol.) was added to a suspension of 6.I.a (10.7 g, 30 mmol.) in a mixture of acetic acid (80 mL, 1.38 mmol.) and acetic anhydride (40 mL, 42 mmol.). The solution was stirred for 18 hours. The solution was poured into water. Extraction with CH_2Cl_2 gave an oily product which was treated in a mixture of CH_2Cl_2 (100 mL) and methanol (100 mL) with concentrated HCl (8 mL), and stirred for 18 hours. Water was added to the mixture and the product was extracted with CH_2Cl_2 and chromatographed, using toluene/ethyl acetate (6/4) as eluting solvent to give 7.4 g of 7.I.a (yield : 67 %), mp : 243°C.

UV $_{\lambda_{\text{max}}}$: 238 nm

IR (KBr, cm^{-1}) : 1733 $\nu\text{C} = \text{O}$; 1713 $\nu\text{C} = \text{O}$; 1656 $\nu\text{C} = \text{O}$ conjugated

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.84 (s, 3H) ; 1.03 (d, 3H) ; 2.06 (s, 3H) ; 2.12 (s, 3H) ; 5.86 (s, 1H).

F/ 17 α -acetoxy-3-ethoxy-15 β -methyl-20-oxo-19-nor-pregna-3,5(6)-diene (8.I.a : $\text{R}_3 = \text{CH}_3$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 0$, alkyl = ethyl)

p-toluenesulfonic acid (40 mg, 0.21 mmol.), 7.I.a (7.34 g, 19.7 mmol.), triethyl orthoformate (7 mL, 42 mmol.) and ethanol (60 mL) were stirred together for 4 hours. Then triethylamine (TEA) (4 mL) was added and the entire solution was poured into 500 mL of an ice/water mixture, stirred for 1 hour, filtered and recrystallized from ethanol containing a small amount of TEA to give 1.87 g of 8.I.a (yield : 23 %), mp : 232°C.

IR (KBr, cm^{-1}) : 1732 $\nu\text{C} = \text{O}$; 1708 $\nu\text{C} = \text{O}$;

UV $_{\lambda_{\text{max}}}$: 241 nm

G/ 17 α -acetoxy-3-ethoxy-6-formyl-15 β -methyl-20-oxo-19-nor-pregna-3,5(6)-diene (9.I.a : $\text{R}_3 = \text{CH}_3$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 0$, alkyl = ethyl)

In a round-bottomed flask POCl_3 (0.6 mL, 6.3 mmol.) was added to DMF (2.88 mL, 37 mmol.) at -10°C. This solution was added to a suspension of compound 8.I.a (1.8 g, 4.4 mmol.) in DMF (10 mL) at -12°C. The red mixture was stirred for 2 hours at -12°C, and treated with 175 mg of NaHCO_3 followed by a solution of CH_3COOK (12 mL) and water (30 mL). The product was extracted with CH_2Cl_2 , evaporated in vacuo to give 1.82 g of 9.I.a (yield : 94 %), mp : 171°C.

UV $_{\lambda_{\text{max}}}$: 324 and 221 nm

IR (KBr, cm^{-1}) : 1734 $\nu\text{C} = \text{O}$; 1652 $\nu\text{C} = \text{O}$; 1608 $\nu\text{C} = \text{O}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.81 (s, 3H) ; 1.01 (d, 3H) ; 1.48 (t, 3H) ; 2.08 (s, 3H) ; 2.11 (s, 3H) ; 6.37 (s, 1H) ; 10.23 (s, 1H).

H/ 17 α -acetoxy-15 β -methyl-6-methyliden-3,20-dioxo-19-nor-pregna-4-ene (10.I.a : $\text{R}_3 = \text{CH}_3$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 0$)

A round-bottomed flask was fitted with a magnetic stirred bar, then compound 9.I.a (1.82 g, 4.2 mmol.), DMF (6 mL) and EtOH (6 mL) were added. NaBH_4 (170 mg, 4.5 mmol.) was added portionwise. Then, a solution of 50 % sulfuric acid (0.8 mL) was added to the mixture. The solution was poured into iced water (200 mL) and the precipitate was filtered to give 1.52 g of crude 10.I.a (yield : 93 %), mp : 200°C.

UV $_{\lambda_{\text{max}}}$: 263 nm

IR (KBr, cm^{-1}) : 1732 $\nu\text{C} = \text{O}$; 1714 $\nu\text{C} = \text{O}$; 1659 $\nu\text{C} = \text{O}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.83 (s, 3H) ; 1.05 (d, 3H) ; 2.04 (s, 3H) ; 2.10 (s, 3H) ; 4.97 (s, 1H) ; 5.19 (s, 1H) ; 6.10 (s, 1H).

I/ 17 α -acetoxy-6,15 β -dimethyl-3,20-dioxo-19-nor-pregna-4,6-diene (11.I.a : $\text{R}_1 = \text{CH}_3$, $\text{R}_3 = \text{CH}_3$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 0$)

A mixture of 10.I.a (980 mg, 2.54 mmol.), Pd/C (5 % with 50 % H_2O) (1.6 g) and MeOH (180 mL) was refluxed during 30 min. The solution was filtered to remove the catalyst. Then, the crude product obtained by evaporating the solvent was flash-chromatographed using toluene/ethyl acetate as eluting solvent (7/3) to give 480 mg of 11.I.a (yield : 49 %), mp : 244°C.

THIS PAGE BLANK (USPTO)

UV λ_{max} : 292 nm

IR (KBr, cm^{-1}) : 1736 $\nu\text{C}=\text{O}$; 1710 $\nu\text{C}=\text{O}$; 1654 $\nu\text{C}=\text{O}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.88 (s, 3H) ; 1.08 (d, 3H) ; 1.88 (s, 3H) ; 2.08 (s, 3H) ; 2.1 (s, 3H) ; 5.95 (s, 1H) ; 6.15 (s, 1H).

5 EXAMPLE 2

17 α -acetoxy-6 α ,15 β -dimethyl-3,20-dioxo-19-nor-pregna-4-ene (12.I.a : $\text{R}_3 = \text{CH}_3$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 0$)

Compound 11.I.a (360 mg, 0.93 mmol.) was hydrogenated in 20 mL of EtOH with 0.3 mL of cyclohexene under stirring over 100 mg of $\text{Pd}/\text{Al}_2\text{O}_3$. The reaction was complete after 1 hour at reflux. The palladium catalyst was filtered. The crude product was obtained by removing the solvent. Crystallization of the crude product in isopropylether gave 100 mg of the title compound (yield : 28 %), mp : 203°C.

IR (KBr, cm^{-1}) : 1734 $\nu\text{C}=\text{O}$; 1714 $\nu\text{C}=\text{O}$; 1661 $\nu\text{C}=\text{O}$

δH (CDCl_3) : 0.85 (s, 3H) ; 1.08 (d, 3H) ; 1.15 (d, 3H) ; 2.05 (s, 3H) ; 2.1 (s, 3H) ; 5.9 (s, 1H)

15 EXAMPLE 3

17 α -acetoxy-6 β ,15 β -dimethyl-3,20-dioxo-19-nor-pregna-4-ene (12.I.b : $\text{R}_3 = \text{CH}_3$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 0$)

20 Preparative HPLC of the mother liquid of 12.I.a yielded the 6 β -methyl isomer.

EXAMPLES 4-5

17 α -acetoxy-6 α ,15 β -dimethyl-3-(E and Z)-hydroxyimino-20-oxo-pregna-4-ene (13.I.a : $\text{R}_2 = \text{H}$, $\text{R}_3 = \text{CH}_3$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 0$)

A mixture of 12.I.a (1 g, 2.58 mmol.), hydroxylamine hydrochloride (250 mg, 3.1 mmol.), pyridine (0.4 mL, 4.9 mmol.) and methanol (10 mL) was refluxed for 2 hours. Evaporation of the solvent gave a crude product which was chromatographed using a mixture of toluene/ethyl acetate (9/1) as eluting solvent to give 560 mg of 17 α -acetoxy-6 α ,15 β -dimethyl-3-E-hydroxyimino-20-oxo-pregna-4-ene (yield : 54 %), mp : 235°C (example 4).

IR (KBr, cm^{-1}) : 3331 νOH ; 1741 and 1702 $\nu\text{C}=\text{O}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.83 (s, 3H) ; 1.04 (d, 3H) ; 1.13 (d, 3H) ; 2.04 (s, 3H) ; 2.09 (s, 3H) ; 5.92 (s, 1H).

and 80 mg of 17 α -acetoxy-6 α ,15 β -dimethyl-3-Z-hydroxyimino-20-oxo-pregna-4-ene (yield : 8 %), mp : 122°C (example 5).

35 IR (KBr, cm^{-1}) : 2923 νOH ; 1736 and 1706 $\nu\text{C}=\text{O}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.82 (s, 3H) ; 1.03 (d, 3H) ; 1.10 (d, 3H) ; 2.06 (s, 3H) ; 2.11 (s, 3H) ; 6.60 (s, 1H).

EXAMPLE 6

40 17 α -acetoxy-6-methyl-15 β ,16 β -methylene-3,20-dioxo-19-nor-pregna-4,6-diene (11.I.b : $\text{R}_3 = \text{H}$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 1$)

A/ 3-methoxy-15 β ,16 β -methylene-19-nor-pregna-1,3,5(10),17(20)-tetraene (3.I.b : $\text{R}_3 = \text{H}$, $\text{R}_5 = \text{H}$, $n = 1$)

3.I.b was prepared from 3-methoxy-15 β ,16 β -methylene-19-nor-17-oxo-pregna-1,3,5(10)-triene obtained as described by O. Schmidt et al., Chem. Ber. 101, 939 (1968) following the process described for 3.I.a (yield : 96 %), mp : 76°C.

IR (KBr, cm^{-1}) : 1605 $\nu\text{C}=\text{C}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.5 (m, 1H) ; 1 (s, 3H) ; 1.7 (d, 3H) ; 3.75 (s, 3H) ; 5.38 (q, 1H) ; 6.75 (m, 2H) ; 7.1 (d, 1H).

50 B/ 17 α -hydroxy-3-methoxy-15 β ,16 β -methylene-20-oxo-19-nor-pregna-1,3,5(10)-triene (4.I.b : $\text{R}_3 = \text{H}$, $\text{R}_5 = \text{H}$, $n = 1$)

4.I.b was prepared from 3.I.b as described for 4.I.a (yield : 47 %), mp : 134°C. IR (KBr, cm^{-1}) : 3508 $\nu\text{O-H}$; 1693 $\nu\text{C}=\text{O}$

55 $^1\text{H-NMR}$ (CDCl_3, δ) : 0.7 (m, 1H) ; 0.8 (s, 3H) ; 2.4 (s, 3H) ; 3.1 (s, 1H) ; 6.7 (m, 2H) ; 7.1 (d, 1H).

C/ 20-(ethylenedioxy)-17 α -hydroxy-3-methoxy-15 β ,16 β -methylene-19-nor-pregna-1,3,5(10)-triene (5.I.b : $\text{R}_3 = \text{H}$, $\text{R}_5 = \text{H}$, $n = 1$)

THIS PAGE BLANK (USPTO)

5.1.b was obtained as described for 5.1.a from compound 4.1.b (yield : 95 %), mp : 166°C.

IR (KBr, cm^{-1}) : 3507 νOH ; 1280 $\nu\text{C-O}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.45 (m, 1H) ; 1.05 (s, 3H) ; 1.5 (s, 3H) ; 3.75 (s, 3H) ; 5 (m, 4H) ; 6.67 (m, 2H) ; 7.1 (d, 1H).

D/ 17 α -hydroxy-15 β ,16 β -methylene-19-nor-3,20-dioxo-pregna-4-ene (6.1.b: $\text{R}_3 = \text{H}$, $\text{R}_5 = \text{H}$, $n = 1$)

6.1.b was prepared from 5.1.b using the same process than for 6.1.a (yield : 63 %), mp : 175°C.

IR (KBr, cm^{-1}) : 3461 νOH ; 1706 $\nu\text{C} = \text{O}$ (20) ; 1661 $\nu\text{C} = \text{O}$ (3) ; 1609 $\nu\text{C} = \text{C}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.65 (m, 1H) ; 0.85 (s, 3H) ; 2.4 (s, 3H) ; 3.05 (s, 1H) ; 5.85 (s, 1H).

E/ 17 α -acetoxy-15 β ,16 β -methylene-3,20-dioxo-19-nor-pregna-4-ene (7.1.b : $\text{R}_3 = \text{H}$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 1$)

7.1.b was obtained from 6.1.b as described for compound 7.1.a (yield : 79 %), mp : 207°C.

IR (KBr, cm^{-1}) : 1732 $\nu\text{C} = \text{O}$; 1715 $\nu\text{C} = \text{O}$; 1659 $\nu\text{C} = \text{O}$; 1615 $\nu\text{C} = \text{C}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.65 (m, 1H) ; 0.8 (s, 3H) ; 2.05 (s, 3H) ; 2.3 (s, 3H) ; 5.89 (s, 1H)

F/ 17 α -acetoxy-3-ethoxy-15 β ,16 β -methylene-20-oxo-19-nor-pregna-3,5(6)-diene (8.1.b : $\text{R}_3 = \text{H}$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, alkyl = ethyl, $n = 1$)

8.1.b was prepared from 7.1.b using the same process than for 8.1.a (yield : 69 %), mp : 164°C.

IR (KBr, cm^{-1}) : 1735 $\nu\text{C} = \text{O}$; 1707 $\nu\text{C} = \text{O}$; 1646-1619 νC

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.65 (m, 1H) ; 0.8 (s, 3H) ; 1.25 (t, 3H) ; 2.1 (s, 3H) ; 2.3 (s, 3H) ; 3.7 (q, 2H) ; 5.85 (s, 1H) ; 5.9 (s, 1H)

G/ 17 α -acetoxy-3-ethoxy-6-formyl-15 β ,16 β -methylene-20-oxo-19-nor-pregna-3,5-diene (9.1.b : $\text{R}_3 = \text{H}$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, alkyl = ethyl, $n = 1$)

9.1.b was obtained by following the same process than 9.1.a from 8.1.b (yield : 93 %), mp : 199°C.

IR (KBr, cm^{-1}) : 1721 $\nu\text{C} = \text{O}$; 1645-1607 $\nu\text{C} = \text{C}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.65 (m, 1H) ; 0.75 (s, 3H) ; 1.35 (t, 3H) ; 2.1 (s, 3H) ; 2.3 (s, 3H) ; 3.9 (m, 2H) ; 6.35 (s, 1H) ; 10.25 (s, 1H)

H/ 17 α -acetoxy-15 β ,16 β -methylene-6-methylidene-3,20-dioxo-19-nor-pregna-4-ene (10.1.b : $\text{R}_3 = \text{H}$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 1$)

10.1.b was obtained by the same process than 10.1.a from 9.1.b (yield : 93 %), mp : 212°C.

IR (KBr, cm^{-1}) : 1732 $\nu\text{C} = \text{O}$; 1717 $\nu\text{C} = \text{O}$; 1659 $\nu\text{C} = \text{O}$; 1625-1585 $\nu\text{C} = \text{C}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.75 (m, 1H) ; 0.8 (s, 3H) ; 2.1 (s, 3H) ; 2.4 (s, 3H) ; 5-5.2 (2s, 2H) ; 6.15 (s, 1H)

I/ 17 α -acetoxy-6-methyl-15 β ,16 β -methylene-3,20-dioxo-19-nor-pregna-4,6-diene (11.1.b : $\text{R}_3 = \text{H}$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 1$)

11.1.b was obtained from 10.1.b as described for compound 11.1.a (yield : 75 %), mp : 205°C.

IR (KBr, cm^{-1}) : 1724 $\nu\text{C} = \text{O}$; 1720 $\nu\text{C} = \text{O}$; 1662 $\nu\text{C} = \text{O}$; 1624-1576 $\nu\text{C} = \text{C}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.75 (m, 1H) ; 0.85 (s, 3H) ; 1.9 (s, 3H) ; 2.1 (s, 3H) ; 2.35 (s, 3H) ; 6 (s, 1H) ; 6.3 (s, 1H).

EXAMPLE 7

17 α -acetoxy-6 α -methyl-15 β ,16 β -methylene-3,20-dioxo-19-nor-pregna-4-ene (12.1.b : $\text{R}_1 = \text{CH}_3$, $\text{R}_3 = \text{H}$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 1$)

12.1.b was prepared following the same process than 12.1.a from 11.1.b (yield : 20 %), mp : 159°C.

IR (KBr, cm^{-1}) : 1724 $\nu\text{C} = \text{O}$; 1722 $\nu\text{C} = \text{O}$; 1674 $\nu\text{C} = \text{O}$; 1604 $\nu\text{C} = \text{C}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.7 (m, 1H) ; 1.18 (d, 3H) ; 2.1 (s, 3H) ; 2.35 (s, 3H) ; 5.9 (s, 1H)

THIS PAGE BLANK (USPTO)

EXAMPLE 8

17 α -ethoxy-15 β ,16 β -methylene-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene (12.l.c : R₁ = CH₃, R₃ = H, R₄ = C₂H₅, R₅ = H, n = 1)

To a stirred suspension of 12.l.b (1.2 g, 3.1 mmol.) in ethanol was added dropwise a solution of NaOH in water (10 %) until the pH was greater than 10 and the mixture was refluxed for 4 hours. Then, the mixture was extracted with CH₂Cl₂ and washed with water. The solvent was removed in vacuo and the crude product was purified by column chromatography on silica gel (toluene/AcOEt 6.5/3.5) to give 0.62 g of 17 α -hydroxy-15 β ,16 β -methylene-6 α -methyl-19-nor-3,20-dione-pregna-4-ene (yield : 70 %).

IR (KBr, cm⁻¹) : 1706 ν C = O ; 1668 ν C = O ; 1610 ν C = C ; 3446 ν O-H

To a stirred mixture of 17 α -hydroxy-15 β ,16 β -methylene-6 α -methyl-19-nor-3,20-dione-pregna-4-ene (6.2 g, 18 mmol.) and KOH (37 mmol.) in DMSO (60 mL) at 23°C was added dimethylsulfate (5 mL, 36 mmol.). After 2 hours, the solution was poured into cold water (500 mL). The crude product was filtered, dissolved in acetone (100 mL) and HCl (20 %) was added to the solution until the pH was 1. After 2 hours, the reaction mixture was concentrated in vacuo, extracted with CH₂Cl₂, washed with water and concentrated to give a residue which was flash-chromatographed on silica gel (toluene/AcOEt 9/1) to give 2 g of a crude product which was crystallized from isopropylether (yield : 10 %), mp : 147°C.

¹H-NMR (CDCl₃, δ) : 0.55 (m, 1H) ; 0.75 (s, 3H) ; 1.15 (d, 3H) ; 1.25 (t, 3H) ; 2.2 (s, 3H) ; 3.15 (m, 1H) ; 3.65 (m, 1H) ; 5.9 (s, 1H).

EXAMPLE 9

17 α -ethoxy-15 β ,16 β -methylene-6-methyl-20-oxo-19-nor-pregna-4,6-diene (11.l.c: R₃ = H, R₄ = C₂H₅, R₅ = H, n = 1)

3,17 α -diethoxy-15 β ,16 β -methylene-6-methyl-19-nor-20-one-pregna-3-5(6)-diene was obtained from 12.l.c following the same process than 8.l.a (yield : 88 %).

¹H-NMR (CDCl₃, δ) : 0.5 (m, 1H) ; 0.7 (s, 3H) ; 1.2 (t, 3H) ; 1.7 (s, 3H) ; 2.15 (s, 3H) ; 3.15 (m, 1H) ; 3.6 (q, 2H) ; 3.8 (m, 1H) ; 5.45 (s, 1H).

To a stirred solution of the previous compound (2.6 g, 6.5 mmol.) in a mixture of acetone (60 mL) and water (1.6 mL) was added DDQ (1.7 g, 7.7 mmol.). After 20 min., the reaction mixture was concentrated in vacuo. The residue was flash-chromatographed twice (toluene/AcOEt : 8/2). Recrystallization from isopropylether gave 175 mg of 11.l.c (yield : 7 %), mp : 185°C.

¹H-NMR (CDCl₃, δ) : 0.6 (m, 1H) ; 0.8 (s, 3H) ; 1.2 (t, 3H) ; 1.9 (s, 3H) ; 2.2 (s, 3H) ; 3.2 (m, 1H) ; 3.7 (m, 1H) ; 5.9 (s, 1H) ; 6.3 (s, 1H).

EXAMPLE 10

17 α -acetoxy-6 α ,7 α -dimethyl-15 β ,16 β -methylene-3,20-dioxo-19-nor-pregna-4-ene (14.l.a : R₂ = CH₃, R₃ = H, R₄ = Ac, R₅ = H, n = 1)

To a stirred suspension of CuI (13.3 g, 70 mmol.) in Et₂O (135 mL) at 0°C was added a solution of MeLi (1.6 M) in Et₂O (88 mL, 140 mmol.). After 0.5 hour, a solution of 11.l.b (5.4 g, 14 mmol.) in THF (70 mL) was added dropwise to the mixture at -5°C over 0.5 hour. The reaction was quenched by addition of a NH₄Cl solution (1000 mL). The cuprous salts were filtered on Celite® and the filtrate was extracted by toluene, washed with water and concentrated in vacuo. The residue was flash-chromatographed (toluene/AcOEt : 9/1) and the crude product was recrystallized from Et₂O to give pure 17 α -acetoxy-6 α ,7 α -dimethyl-15 β ,16 β -methylene-19-nor-3,20-dioxo-pregna-5(6)-ene (yield : 7 %).

¹H-NMR (CDCl₃, δ) : 0.55 (m, 1H) ; 0.7 (s, 3H) ; 0.9 (d, 3H) ; 1.6 (s, 3H) ; 2.05 (s, 3H) ; 2.1 (s, 3H)

A solution of the previous compound (0.4 g, 1 mmol.) in a mixture of acetone (10 mL) and water (5 mL) was acidified with concentrated HCl until the pH was 1. After 6 hours, the reaction was concentrated, extracted with CH₂Cl₂, washed with water and the solvent was removed. The crude product was chromatographed on silica gel (toluene/AcOEt : 7/3 v/v) to give 0.2 g of the title compound (yield : 50 %), mp : 170°C.

¹H-NMR (CDCl₃, δ) : 0.7 (m, 1H) ; 0.75 (d, 3H) ; 0.85 (s, 3H) ; 1.1 (d, 3H) ; 2.1 (s, 3H) ; 2.3 (s, 3H) ; 5.85 (s, 1H).

EXAMPLE 11

17 α -acetoxy-6 α ,7 α -dimethyl-3,20-dioxo-19-nor-pregna-4-ene (14.l.b: R₂ = CH₃, R₃ = H, R₄ = Ac, R₅ = H, n = 0)

17 α -acetoxy-3-ethoxy-6-methyl-19-nor-20-one-pregna-3-5(6)-diene was obtained from 17 α -acetoxy-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene prepared using the procedures described in DE-A-2 148 261 following the same proc-

HIS PAGE BLANK (USPTO)

ess than for 8.I.a (yield : 90 %).

IR (KBr, cm^{-1}) : 1730 $\nu\text{C}=\text{O}$; 1652-1621 $\nu\text{C}=\text{C}$

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.6 (s, 3H) ; 1.3 (t, 3H) ; 2.0 (s, 3H) ; 2.1 (s, 3H) ; 3.75 (m, 2H) ; 5.4 (s, 1H).

This compound (15 g, 3.75 mmol.) was dissolved in acetone/water and treated with DDQ as described before for 11.I.c After a flash-chromatography (toluene/AcOEt 7/3) to remove the hydroquinone, the crude product (3.7 g) was used without other purification and following the process described for 14.I.a, 0.6 g of pure 17 α -acetoxy-6,7 α -dimethyl-19-nor-3,20-dioxo-pregna-5(6)-ene was obtained (yield : 4 %).

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.7 (s, 3H) ; 0.9 (d, 3H) ; 1.6 (s, 3H) ; 2.05 (s, 3H) ; 2.1 (s, 3H)

Compound 14.I.b was obtained from the previous compound following the same process than for 14.I.a (yield : 30 %), mp : 222°C.

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.65 (d, 3H) ; 0.7 (s, 3H) ; 1.2 (d, 3H) ; 2.0 (s, 3H) ; 2.1 (s, 3H) ; 5.8 (s, 1H).

EXAMPLE 12

17 α -acetoxy-7 α -ethyl-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene (14.I.c : $\text{R}_2 = \text{C}_2\text{H}_5$, $\text{R}_3 = \text{H}$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 0$)

Using the procedure described for 14.I.b but replacing methyl lithium by ethyl magnesium chloride in the alkylation step, compound 14.I.c was obtained in 17 % yield, mp : 200° C.

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.70 (s, 3H) ; 0.98 (m, 3H) ; 1.12 (d, 3H) ; 2.05 (s, 3H) ; 2.15 (s, 3H) ; 2.60 (m, 1H) ; 5.89 (s, 1H).

EXAMPLES 13-14

17 α -acetoxy-3-(Z and E)-hydroxyimino-6 α ,7 α -dimethyl-20-oxo-19-nor-pregna-4-ene (13.I.b : $\text{R}_2 = \text{CH}_3$, $\text{R}_3 = \text{H}$, $\text{R}_4 = \text{Ac}$, $\text{R}_5 = \text{H}$, $n = 0$)

To a solution of 17 α -acetoxy-6 α ,7 α -dimethyl-3,20-dioxo-19-nor-pregna-4-ene (2 g, 5.18 mmol.) in dioxane (100 mL) was added successively hydroxylamine hydrochloride (0.755 g, 10.36 mmol.) and pyridine (5 mL). The mixture was heated to reflux for 1 hour. Then, the reaction was poured into iced water and acidified with a 1N HCl solution. Extraction with methylene chloride and evaporation of the solvent gave 1.92 g of a crude product which was flash-chromatographed using toluene/AcOEt as eluting solvent.

The first product eluted was the E isomer and was crystallized from ethanol (0.650 g, yield: 31.3%), mp > 250°C (example 13).

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.647-0.652 (d, 3H) ; 0.69 (s, 3H) ; 1.071-1.10 (d, 3H) ; 2.05 (s, 3H) ; 2.12 (s, 3H) ; 2.95 (m, 2H) ; 5.88 (s, 1H) ; 8.25 (bs, 1H)

It was followed by the Z isomer which was crystallized from a mixture of absolute ethanol and diisopropyl ether (0.170 g, yield: 16.4 %), mp : 208°C (example 14).

$^1\text{H-NMR}$ (CDCl_3, δ) : 0.635-0.671 (d, 3H) ; 0.688 (s, 3H) ; 1.11-1.15 (d, 3H) ; 2.05 (s, 3H) ; 2.123 (s, 3H) ; 2.95 (m, 1H) ; 6.548 (s, 1H).

EXAMPLES 15-31

The following examples illustrate the preparation of representative pharmaceutical formulations containing a compound of formula (I) :

Pharmaceutical formulations for oral administration

EXAMPLE 15

Tablets with delayed release.

Unit formulation for various dosages :

THIS PAGE BLANK (USPTO)

Compound of formula (I)	0.50 to 10.00 mg
Aerosil® 200	0.37 to 0.50 mg
Precirol® ATO 5	1.85 to 2.25 mg
Methocel® E4	55.00 to 70.00 mg
Avicel® PH 101	10.00 to 20.00 mg
Lactose qs for 1 tablet of	185.00 to 200.00 mg

EXAMPLE 16

Tablets with fast release.

Unit formulation for various dosages :

Compound of formula (I)	0.50 to 10.00 mg
Aerosil® 200	0.37 to 0.50 mg
Precirol® ATO 5	1.85 to 2.50 mg
Avicel® PH 102	50.00 to 70.00 mg
Explotab® or polyplasdone® XL	5.00 to 25.00 mg
Lactose qs for 1 tablet of	185.00 to 200.00 mg

EXAMPLE 17

Tablets.

Unit formulation for various dosages :

Compound of formula (I)	0.50 to 10.00 mg
Aerosil® 200	0.30 to 0.50 mg
Compritol®	1.50 to 3.00 mg
Avicel® PH 101	55.00 to 70.00 mg
Lactose qs for 1 tablet of	185.00 to 200.00 mg

Capsules.

Unit formulation for various dosages :

Compound of formula (I)	0.50 to 10.00 mg
Oleic acid qs for 1 capsule	250.00 to 260.00 mg

THIS PAGE BLANK (USPTO)

Coating : gelatine, preservatives, glycerol

Pharmaceutical formulations for vaginal administration

EXAMPLE 18

Vaginal gynaecologic capsule.

Unit formulation for a capsule :

Compound of formula (I)	0.50 to 15.00 mg
Vaseline	150.00 to 200.00 mg
Sorbitol sesquioleate	150.00 to 200.00 mg
Synthetic perhydrosqualène qs for 1 capsule of 1.85 g	

Coating : gelatine, glycerol, preservatives for a soft capsule weighing 2.55 g

EXAMPLE 19

Vaginal suppository.

Unit formulation for a suppository :

Compound of formula (I)	0.50 to 15.00 mg
Witepsol® H35 or H37 qs for a suppository of 3.00 g	

EXAMPLE 20

Vaginal suppository with slow release.

Unit formulation for a suppository of 3.00 g :

Compound of formula (I)	0.50 to 30.00 mg
Witepsol® H19 or H35	1.00 to 1.30 g
Suppocire® BM or NAI50	1.00 to 1.50 g
Precirol®	0.00 to 0.20 g

THIS PAGE BLANK (USPTO)

Pharmaceutical formulations for cutaneous or gynaecologic use

EXAMPLE 21

5 Bioadhesive gel for cutaneous or gynaecologic use.

Formula for 100 g :

Compound of formula (I)	0.10 to 1.00 g
Polyethylene glycol	0.00 to 6.00 g
Transcutol®	0.00 to 6.00 g
Carboxypolyvinyl polymer	0.50 to 1.00 g
Preservatives	0.30 mg
Triethanolamine qs pH 6.5	
Purified water qs for 100 g	

EXAMPLE 22

25 Gel for cutaneous use.

Formula for 100 g :

Compound of formula (I)	0.10 to 2.00 g
Polyethylene glycol or Transcutol®	1.00 to 4.00 g
Ethyl alcohol	20.00 to 40.00 g
Carboxypolyvinyl polymer	0.50 to 2.00 g
Triethanolamine qs pH 6.5	
Purified water qs for 100 g	

EXAMPLE 23

Patches.

45 Content of the reservoir or matrix.
Preparation for 100 g

Compound of formula (I)	0.25 to 20.00 mg
Enhancer*	0.20 to 0.50 g
Suspending agent (HPMC** or Aerosil®)	0.10 to 1.00 g
Ethyl alcohol or silicone oil qs for 100 g	

* enhancer = isopropyl palmitate, propyleneglycol, menthol, azone, N,N-dimethylacetamide, mono- or disubstituted pyrrolidone derivatives ;

**HPMC = hydroxypropylmethyl cellulose

THIS PAGE BLANK (USPTO)

Pharmaceutical formulations for percutaneous administration

5 EXAMPLE 24

Implants.

Formulation for 100 g of material to be extruded :

Compound of formula (I)	1.00 to 5.00 g
Polymers (EVA, Polyorthocarbonates) qs for 100 g	

The temperature of the mixture shall not exceed 150°C in order not to impair the active ingredient.

20 *Implants with reservoir.*

The implant is a sealed silastic tubing having a length of 2.5 to 3.5 cm, a thickness of 0.4 to 0.8 mm and a diameter of 1.40 to 2mm. The preparation is formulated as a suspension as follows :
For 100 g of suspension.

Compound of formula (I)	30.00 to 50.00 g
Suspending agent qs for 100 g	

50 mg of the suspension for one implant.

35 EXAMPLE 25

Injectible depot.

Unit formulation for a flask of 5 ml.

Compound of formula (I)	10.00 to 50.000 mg
Polyethylene glycol 4000	100.00 to 200.000 mg
Preservatives	0.006 mg
Sodium chloride and citrate	0.150 mg
Distilled water for injection qs for 5.00 ml	

50 EXAMPLE 26

Injectible suspension.

Unit formulation for a 2 ml ampoule :

THIS PAGE BLANK (USPTO)

Compound of formula (I)	5.00 to 10.00 mg
-------------------------	------------------

Suspension solution

Polysorbate® 80	0.015 g
Sodium carboxymethyl cellulose	0.010 g
Sodium chloride	0.010 g
Purified water for injection qs for 2.00 ml	

EXAMPLE 27

Intra-uterine device with reservoir.

Device with a silastic reservoir having a length of 2.5 to 3.5 cm and a thickness of 0.4 to 0.8 mm. The preparation is formulated as a suspension as follows : For 100 g of suspension.

Compound of formula (I)	0.60 to 1.00 g
suspended to :	
Suspending agent (Aerosil® or HPMC)	0.50 g
Synthetic perhydrogenalene qs for 100 g	

EXAMPLE 28

Bioadhesive gynaecological foam.

Formula for a dispenser of 50 g and a spray valve (2 ml)

Compound of formula (I)	0.10 to 0.25 g
Carboxypolyvinyl polymer	0.50 to 1.00 g
Isobutane	5.00 to 10.00 g
Excipient base F25/1 qs for 50.00 g	

Shake the suspension before use.

Dispensed dosage from 2.00 to 10.00 mg

THIS PAGE BLANK (USPTO)

Pharmaceutical formulation for nasal administration**EXAMPLE 29**5 *Nasal suspension.*

Formulation for 100 g of suspension :

Compound of formula (I)	5.00 to 50.00 mg
Aerosil® PH 101	10.00 to 20.00 mg
Sodium carboxymethyl cellulose	5.00 to 50.00 mg
Phenylethyl alcohol	2.00 to 10.00 mg
Polysorbate® 80	10.00 to 20.00 mg
Purified water qs for 100 g	

Shake the suspension before use
 Dispensed dosage from 0.5 to 2.5 mg

Pharmaceutical formulations for ophtalmic administration**EXAMPLE 30***Ophtalmic solution (collyrium).*

Formulation for 100 g of solution. Container of 5 ml with glass droppers :

Compound of formula (I)	0.50 to 1.00 g
Glycerol	5.00 g
Polyvidone or sodium chloride	0.50 to 0.90 g
Sorbitol	4.00 g
Preservatives (benzalkonium chloride or Cetrimide®)	0.01 g
EDTA	0.01 g
Distilled water qs for 100 g	

The solution is a sterile aqueous solution ; it may contain stabilisers and antimicrobial agents.
 The recommended dose is one drops four times daily.

EXAMPLE 31*Ophtalmic gel.*

Formulation for 100 g of gel. Container : collapsible tube

THIS PAGE BLANK (USPTO)

Compound of formula (I)	0.50 to 2.00 g
Cetrimide®	0.01 g
Sorbitol	4.00 g
EDTA	0.01 g
Carboxypolyvinyl polymers (Carbopol® 971)	0.14 to 0.20 g
Sodium hydroxyde 10 % qs pH 6.5	
Purified water qs for 100 g.	


The sterile aqueous gel is packed in a collapsible tube.
The recommended dose is one drop one or two times daily.

Typical examples of the compounds of formula (I) provided by this invention include :

- 17 α -acetoxy-6,15 β -dimethyl-3,20-dioxo-19-nor-pregna-4,6-diene
- 17 α -acetoxy-6 α ,15 β -dimethyl-3,20-dioxo-19-nor-pregna-4-ene
- 17 α -acetoxy-6 β ,15 β -dimethyl-3,20-dioxo-19-nor-pregna-4-ene
- 17 α -acetoxy-6 α ,15 β -dimethyl-3-E-hydroxyimino-20-oxo-19-nor-pregna-4-ene
- 17 α -acetoxy-6 α ,15 β -dimethyl-3-Z-hydroxyimino-20-oxo-19-nor-pregna-4-ene
- 17 α -acetoxy-6-methyl-15 β ,16 β -methylene-3,20-dioxo-19-nor-pregna-4,6-diene
- 17 α -acetoxy-6 α -methyl-15 β ,16 β -methylene-3,20-dioxo-19-nor-pregna-4-ene
- 17 α -ethoxy-15 β ,16 β -methylene-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene
- 17 α -ethoxy-15 β ,16 β -methylene-6-methyl-20-oxo-19-nor-pregna-4,6-diene
- 17 α -acetoxy-6 α ,7 α -dimethyl-15 β ,16 β -methylene-3,20-dioxo-19-nor-pregna-4-ene
- 17 α -acetoxy-7 α -ethyl-6 α -methyl-3,20-dioxo-19-nor-pregna-4-ene
- 17 α -acetoxy-6 α ,7 α -dimethyl-3,20-dioxo-19-nor-pregna-4-ene
- 17 α -acetoxy-6 α -methyl-7 α -ethyl-3,20-dioxo-19-nor-pregna-4-ene
- 17 α -acetoxy-3-Z-hydroxyimino-6 α ,7 α -dimethyl-20-oxo-19-nor-pregna-4-ene
- 17 α -acetoxy-3-E-hydroxyimino-6 α ,7 α -dimethyl-20-oxo-19-nor-pregna-4-ene

Claims

1. A compound having the following general formula (I):



wherein :

- each of R_1 and R_2 is hydrogen or a (C₁-C₆)alkyl, R_1 and R_2 being not simultaneously hydrogen ;
- R_3 is hydrogen, a (C₁-C₆)alkyl or a (C₁-C₆)alkoxy ;
- R_4 is hydrogen, a (C₁-C₆)alkyl or a group -COR₆ where R_6 is a (C₁-C₆)alkyl ;
- R_5 is hydrogen or a (C₁-C₆)alkyl ;
- n is zero or one ;

THIS PAGE BLANK (USPTO)

X is oxygen or an hydroxyimino group ; and

the dotted line may represent a double bond ; provided that when $n = 0$, R_3 is hydrogen only if both R_1 and R_2 are a (C_1-C_6) alkyl.

- 5 2. A compound according to claim 1, wherein R_1 and R_3 are a (C_1-C_6) alkyl, R_2 and R_5 are hydrogen, R_4 is a group - COR_6 , n is zero and R_6 and X are as defined for (I) in claim 1.
3. A compound according to claim 1, wherein R_1 is a (C_1-C_6) alkyl, R_3 and R_5 are hydrogen, R_4 is a group - COR_6 , n is one, and X , R_2 and R_6 are as defined for (I) in claim 1;
- 10 4. A compound according to claim 1, wherein R_1 and R_4 are a (C_1-C_6) alkyl, R_2 , R_3 and R_5 are hydrogen, n is one and X is as defined for (I) in claim 1.
- 15 5. A compound according to claim 1, wherein R_1 and R_2 are a (C_1-C_6) alkyl, R_3 and R_5 are hydrogen, R_4 is a group - COR_6 , n is zero and R_6 and X are as defined for (I) in claim 1.
6. A pharmaceutical composition containing (i) an effective amount of a compound of formula (I) according to any one of claims 1-5 and (ii) suitable excipients.
- 20 7. A pharmaceutical composition according to claim 6, which contains from 0.01 wt% to 99.99 wt% of the compound of formula (I).
8. A pharmaceutical composition according to claim 6 or 7, which is a contraceptive composition.
- 25 9. A contraceptive composition according to claim 8, which further contains an effective amount of an oestrogen.
10. Use of a compound of formula (I) according to any one of claims 1-5 for the preparation of a medicament intended for treating or preventing gynaecological disorders associated to an oestrogen/progesterone imbalance.
- 30 11. Use of a compound of formula (I) according to any one of claims 1-5 for the preparation of a medicament intended for inhibiting oestrogen transformation of endometrium.
12. Use of a compound of formula (I) according to any one of claims 1-5 for the preparation of a medicament intended for inhibiting gonadotropic/gonadal secretions.
- 35 13. Use of a compound of formula (I) according to any one of claims 1-5, alone or in combination with an oestrogen, for the preparation of a contraceptive agent.
- 40 14. Use of a compound of formula (I) according to any one of claims 1-5, alone or in combination with an oestrogen for the preparation of a medicament intended for postmenopausal hormone replacement therapy.

45

50

55

THIS PAGE BLANK (USPTO)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 40 0145

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Y	FR-A-2 111 097 (CIBA-GEIGY A.G.) 2 June 1972 * example 1 *	1-14	C07J7/00 A61K31/57 C07J53/00 C07J41/00
Y	DE-A-20 48 231 (CIBA-GEIGY A.G.) 29 April 1971 * the whole document *	1-14	//C07J13/00, C07J17/00
Y	US-A-3 759 962 (ANNER G ET AL) 18 September 1973 * the whole document *	1-14	
Y	ARZNEIMITTEL FORSCHUNG DRUG RESEARCH., vol. 33, no. 5, 1983, AULENDORF DE, pages 710-715, XP002005431 J. PARIS ET AL: "The Pharmacological Profile of TX 066 (17.alpha.-Acetoxy-6-methyl-19-nor-4,6-pregnadiene-3,20-dione)" * the whole document *	1-14	
Y	ARZNEIMITTEL FORSCHUNG DRUG RESEARCH., vol. 45, no. 1, 1995, AULENDORF DE, pages 70-74, XP002005432 I. DUC ET AL: "Antiandrogenic Properties of Nomegestrol Acetate" * the whole document *	1-14	TECHNICAL FIELDS SEARCHED (Int.Cl.6) C07J A61K
Y	FR-A-2 271 833 (GASTAUD JEAN MARIE) 19 December 1975 * examples 4-6 *	1-14	
Y	FR-A-2 199 993 (SCHERING AG) 19 April 1974 * examples 4-6,8 *	1-14	
Y	DE-A-20 14 834 (F. HOFFMANN LA ROCHE & CO A.G.) 5 November 1970 * example 1 *	1-14	
		-/--	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12 June 1996	Examiner Watchorn, P
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>			

THIS PAGE BLANK (USPTO)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 96 40 0145

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Y	CH-A-509 997 (F. HOFFMANN LA ROCHE & CO A.G.) 15 July 1971 * example 1 * -----	1-14	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12 June 1996	Examiner Watchorn, P
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 01.82 (P04C01)

THIS PAGE BLANK (USPTO)